<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Subtitle 52 PREVENTIVE MEDICINE | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.52/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.52/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|52|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|52" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/10.52"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Subtitle 52 PREVENTIVE MEDICINE | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.52/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.52/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|52" data-search-heading="">
                  <span title="Subtitle 52 PREVENTIVE MEDICINE">Subtitle 52 PREVENTIVE MEDICINE</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|52">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/10.52">Subtitle 52 PREVENTIVE MEDICINE</h1>
                <h2 id="/us/md/exec/comar/10.52.01" data-order="|10|52|01|" data-ref-path="10|52|01" class="h__chapter">Chapter 01 Opioid-Associated Disease Prevention and Outreach Programs</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: April 24, 2017 (44:8 Md. R. 404)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§24-901—24-909, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.01.01" data-order="|10|52|01|.01|" data-ref-path="10|52|01|.01" class="h__section">.01 Purpose and Scope.</h3>
                <p>This chapter:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.01#A">A.</span> Defines an opioid-associated disease prevention and outreach program; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.01#B">B.</span> Sets forth:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.01#B(1)">(1)</span> The responsibilities of the Maryland Department of Health and local health departments in establishing opioid-associated disease prevention and outreach programs; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.01#B(2)">(2)</span> Requirements for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.01#B(2)(a)">(a)</span> Monitoring and evaluating opioid-associated disease prevention and outreach programs; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.01#B(2)(b)">(b)</span> Research conducted in collaboration with an opioid-associated disease prevention and outreach program.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.01.02" data-order="|10|52|01|.02|" data-ref-path="10|52|01|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#A">A.</span> In this chapter, the following terms have the meaning indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(1)">(1)</span> “Applicant” means a local health department or community-based organization seeking to establish an opioid-associated disease prevention and outreach program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(2)">(2)</span> Body Fluid.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(2)(a)">(a)</span> “Body fluid” means any fluid containing visible blood, semen, or vaginal secretions.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(2)(b)">(b)</span> “Body fluid” does not include cerebrospinal fluid, synovial fluid, breast milk, amniotic fluid, saliva, stool, nasal secretions, sputum, tears, urine, or vomitus.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(3)">(3)</span> “Community-based organization (CBO)” means a public or private organization that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(3)(a)">(a)</span> Is representative of a community or significant segments of a community; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(3)(b)">(b)</span> Provides educational, health, or social services to individuals in the community.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(4)">(4)</span> “Department” means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(5)">(5)</span> “Harm reduction education” means education on practical strategies:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(5)(a)">(a)</span> To reduce negative consequences associated with drug use; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(5)(b)">(b)</span> That reflect specific individual and community needs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(6)">(6)</span> “HIV” means the human immunodeficiency virus that causes acquired immune deficiency syndrome (AIDS).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(7)">(7)</span> “Infection control” means infection prevention and control measures that ensure the protection of individuals who are vulnerable to acquiring an infection both in the general community and while receiving health care services in a range of settings.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(8)">(8)</span> “Injection supplies” means materials used to inject drugs including, but not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(8)(a)">(a)</span> Cookers;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(8)(b)">(b)</span> Water; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(8)(c)">(c)</span> Cotton.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(9)">(9)</span> “Naloxone” means an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory or central nervous system depression.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(10)">(10)</span> “OADPO program” means an opioid-associated disease prevention and outreach program established by a local health department or community-based organization that provides services including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(10)(a)">(a)</span> Dissemination of hypodermic needles or syringes and other preventive means for curtailing the spread of HIV and viral hepatitis;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(10)(b)">(b)</span> Overdose prevention education; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(10)(c)">(c)</span> Harm reduction education.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(11)">(11)</span> “Participant” means an individual who has registered with an OADPO program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(12)">(12)</span> “Sexually transmitted infection (STI)” means an infection passed from one person to another person through sexual contact.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(13)">(13)</span> “Viral hepatitis” means inflammation of the liver caused by the hepatitis A, B, C, D, and E viruses.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.02#B(14)">(14)</span> “Wound care” means treatment of the symptoms of infections that may result from using drugs.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.01.03" data-order="|10|52|01|.03|" data-ref-path="10|52|01|.03" class="h__section">.03 Program Establishment.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.03#A">A.</span> Effective October 1, 2016, a local health department or CBO may establish an OADPO program with approval from the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.03#A(1)">(1)</span> Department; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.03#A(2)">(2)</span> Local health officer of the county in which OADPO program operations are proposed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.03#B">B.</span> When proposing an OADPO program, a local health department may collaborate with:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.03#B(1)">(1)</span> A CBO; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.03#B(2)">(2)</span> Another local health department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.03#C">C.</span> A CBO may operate an OADPO program in multiple counties if approved by the local health officer in each county where the OADPO program proposes to operate.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.01.04" data-order="|10|52|01|.04|" data-ref-path="10|52|01|.04" class="h__section">.04 Application Process.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#A">A.</span> An applicant:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#A(1)">(1)</span> Shall submit an application to establish an OADPO program to the Department that includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#A(1)(a)">(a)</span> Responses to all applicable questions; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#A(1)(b)">(b)</span> Any supporting documentation indicated on the application;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#A(2)">(2)</span> May voluntarily withdraw an application at any time; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#A(3)">(3)</span> May submit a new application at any time.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#B">B.</span> The Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#B(1)">(1)</span> Distribute the application to establish an OADPO program to the local health officer in each jurisdiction where the OADPO program proposes to operate;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#B(2)">(2)</span> Request additional information or changes to the application if necessary; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#B(3)">(3)</span> Respond in writing to the applicant within 60 calendar days indicating the disposition of the application and explanation of the decision.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#C">C.</span> The Department and the local health officer in each jurisdiction where the OADPO program proposes to operate shall jointly:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#C(1)">(1)</span> Review the application; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#C(2)">(2)</span> Either:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#C(2)(a)">(a)</span> Approve the application if the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#C(2)(a)(i)">(i)</span> Application is complete; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#C(2)(a)(ii)">(ii)</span> OADPO program meets the requirements of Regulations .05 and .06 of this chapter; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#C(2)(b)">(b)</span> Disapprove the application if the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#C(2)(b)(i)">(i)</span> Application does not provide sufficient information or documentation on the OADPO program; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#C(2)(b)(ii)">(ii)</span> OADPO program does not meet the requirements of Regulations .05 and .06 of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#D">D.</span> An applicant whose application is disapproved may appeal the decision to the Deputy Secretary for Public Health Services by submitting the request in writing to the Deputy Secretary for Public Health Services within 30 calendar days of the date postmarked on the notice of disapproval.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#E">E.</span> If an applicant submits an appeal, the Deputy Secretary for Public Health Services shall within 60 days:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#E(1)">(1)</span> Grant or deny the appeal; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#E(2)">(2)</span> Respond in writing to the applicant:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#E(2)(a)">(a)</span> Indicating whether the appeal has been granted or denied; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.04#E(2)(b)">(b)</span> Providing an explanation of the decision.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.01.05" data-order="|10|52|01|.05|" data-ref-path="10|52|01|.05" class="h__section">.05 Program Design and Operation.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A">A.</span> The CBO or local health department approved to operate an OADPO program:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(1)">(1)</span> Shall provide protocols for the safety and security of OADPO program locations, equipment, and staff in accordance with <a class="internal-link " href="/us/md/exec/comar/10.52.01.06" title=".06 Program Security.">Regulation .06 of this chapter</a> that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(1)(a)">(a)</span> Control the dissemination of hypodermic needles and syringes; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(1)(b)">(b)</span> Allow for a full accounting of the number of hypodermic needles and syringes managed by the program;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(2)">(2)</span> Shall offer participants:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(2)(a)">(a)</span> Overdose prevention education;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(2)(b)">(b)</span> Access to or a referral to obtain naloxone; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(2)(c)">(c)</span> Harm reduction education;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(3)">(3)</span> Shall ensure that all OADPO program staff have:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(3)(a)">(a)</span> Appropriate levels of expertise in working with individuals who inject drugs;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(3)(b)">(b)</span> Knowledge of harm reduction strategies; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(3)(c)">(c)</span> Skills in implementing harm reduction strategies;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(4)">(4)</span> Shall ensure that all OADPO program staff receive training approved by the Department to work with injection drug users and to provide referrals to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(4)(a)">(a)</span> Community services;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(4)(b)">(b)</span> Counseling; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(4)(c)">(c)</span> Preventative education;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(5)">(5)</span> Shall ensure that all OADPO program staff demonstrate sensitivity to participant differences including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(5)(a)">(a)</span> Cultural;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(5)(b)">(b)</span> Behavioral; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(5)(c)">(c)</span> Values;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(6)">(6)</span> Shall ensure that information collected to identify OADPO program participants is kept confidential according to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(6)(a)">(a)</span> Health-General Article, §24-906(b), Annotated Code of Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(6)(b)">(b)</span> 42 CFR Part 2;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(7)">(7)</span> Shall ensure that there is a method of identification and authorization for OADPO program staff members who have access to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(7)(a)">(a)</span> Hypodermic needles;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(7)(b)">(b)</span> Syringes; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(7)(c)">(c)</span> OADPO program records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(8)">(8)</span> Shall develop and provide a protocol for linking participants to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(8)(a)">(a)</span> Substance abuse treatment services;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(8)(b)">(b)</span> Testing for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(8)(b)(i)">(i)</span> HIV;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(8)(b)(ii)">(ii)</span> Viral hepatitis; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(8)(b)(iii)">(iii)</span> STIs;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(8)(c)">(c)</span> Reproductive health services;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(8)(d)">(d)</span> Wound care; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(8)(e)">(e)</span> Naloxone;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(9)">(9)</span> Shall disseminate hypodermic needles or syringes and other preventive means for curtailing the spread of HIV and viral hepatitis at no cost to participants, including but not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(9)(a)">(a)</span> Injection supplies; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(9)(b)">(b)</span> Safer sex supplies; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)">(10)</span> May not discriminate against participants based on factors including but not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(a)">(a)</span> Culture;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(b)">(b)</span> Language;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(c)">(c)</span> Ability;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(d)">(d)</span> Socioeconomic status;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(e)">(e)</span> Sexual orientation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(f)">(f)</span> Gender identity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(g)">(g)</span> Age;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(h)">(h)</span> Religion;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(i)">(i)</span> Race; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#A(10)(j)">(j)</span> Ethnicity.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#B">B.</span> Identification Card. OADPO program staff shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#B(1)">(1)</span> Give each participant an identification card that includes the participant’s OADPO program identification number;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#B(2)">(2)</span> Advise participants to carry the identification card with them at all times; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#B(3)">(3)</span> If the identification card is lost by a participant, re-issue an identification card to the participant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#C">C.</span> The CBO or local health department approved to operate an OADPO program may offer other services to OADPO program participants, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#C(1)">(1)</span> Testing for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#C(1)(a)">(a)</span> HIV;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#C(1)(b)">(b)</span> Viral hepatitis; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#C(1)(c)">(c)</span> STIs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#C(2)">(2)</span> Wound care;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#C(3)">(3)</span> Reproductive health services; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.05#C(4)">(4)</span> Substance abuse counseling, treatment, and recovery services.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.01.06" data-order="|10|52|01|.06|" data-ref-path="10|52|01|.06" class="h__section">.06 Program Security.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#A">A.</span> An OADPO program shall implement protocols for the safety and security of program locations, equipment, and staff.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B">B.</span> OADPO program staff shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(1)">(1)</span> Wear suitable clothing, including closed footwear, at all times;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(2)">(2)</span> Treat all body fluids as potentially infectious and follow infection control protocols at all times including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(2)(a)">(a)</span> Use of barriers including gloves;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(2)(b)">(b)</span> Immediate washing of hands and other skin surfaces after contact with body fluids; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(2)(c)">(c)</span> Careful handling and disposal of sharp instruments during and after use;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(3)">(3)</span> When working off-site, have access to a communications system that allows staff to stay in contact with:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(3)(a)">(a)</span> Other staff; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(3)(b)">(b)</span> Emergency support;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(4)">(4)</span> Obtain consent of the owner or occupier of private property to enter the property to dispense or collect syringes or hypodermic needles; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#B(5)">(5)</span> Transport biohazardous waste to the disposal facility using a method that does not put any individuals at risk.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C">C.</span> OADPO programs shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(1)">(1)</span> Have a critical incident procedure that outlines processes and responsibilities of program staff for managing incidents including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(1)(a)">(a)</span> Participant aggression;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(1)(b)">(b)</span> Threats of violence; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(1)(c)">(c)</span> Other hazardous situations;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(2)">(2)</span> Have available the following safety equipment during program operations:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(2)(a)">(a)</span> Puncture resistant utility gloves;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(2)(b)">(b)</span> Bleach; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(2)(c)">(c)</span> Forceps or tongs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(3)">(3)</span> Have facilities that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(3)(a)">(a)</span> Have adequate lighting; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(3)(b)">(b)</span> Are free from clutter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(4)">(4)</span> Have a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(4)(a)">(a)</span> Contract with a licensed biohazardous waste disposal facility to receive biohazardous waste; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(4)(b)">(b)</span> Written agreement that authorizes the OADPO program to drop off used syringes contained in a locked sharps container for safe disposal with a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(4)(b)(i)">(i)</span> Hospital;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(4)(b)(ii)">(ii)</span> Doctor’s office;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(4)(b)(iii)">(iii)</span> Pharmacy;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(4)(b)(iv)">(iv)</span> Medical testing facility; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#C(4)(b)(v)">(v)</span> Other facility that already receives and safely disposes of hazardous waste.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D">D.</span> To prevent needlestick injuries, OADPO program participants, staff, volunteers, and any other individuals present at the facility in an occupational capacity shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(1)">(1)</span> Receive education on safety protocols for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(1)(a)">(a)</span> Carrying and handling:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(1)(a)(i)">(i)</span> Syringes;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(1)(a)(ii)">(ii)</span> Hypodermic needles; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(1)(a)(iii)">(iii)</span> Other sharps;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(1)(b)">(b)</span> The transport and disposal of biohazardous waste; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(1)(c)">(c)</span> Infection control;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(2)">(2)</span> Refrain from touching, without safety equipment, used:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(2)(a)">(a)</span> Hypodermic needles;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(2)(b)">(b)</span> Syringes; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(2)(c)">(c)</span> Injection supplies; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(3)">(3)</span> Be encouraged to wear clothing at all times that provides protection against needlestick injuries including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(3)(a)">(a)</span> Long pants; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#D(3)(b)">(b)</span> Long-sleeved shirts.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E">E.</span> Use of Sharps Containers.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(1)">(1)</span> Used hypodermic needles, syringes, and injection supplies collected by the program from participants shall be placed in sharps containers.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(2)">(2)</span> Sharps containers:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(2)(a)">(a)</span> Shall be leak proof;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(2)(b)">(b)</span> Shall be rigid;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(2)(c)">(c)</span> Shall be puncture resistant;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(2)(d)">(d)</span> Shall be labeled as containing sharps;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(2)(e)">(e)</span> Shall be placed on a level, secure surface that is a safe distance between participants and staff or volunteers during syringe exchange transactions; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(2)(f)">(f)</span> May not be more than 75 percent full.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)">(3)</span> Participants shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(a)">(a)</span> Place into the sharps container all used:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(a)(i)">(i)</span> Hypodermic needles;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(a)(ii)">(ii)</span> Syringes; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(a)(iii)">(iii)</span> Injection supplies;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(b)">(b)</span> When possible, retrieve supplies that fall outside of the sharps container, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(b)(i)">(i)</span> Hypodermic needles;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(b)(ii)">(ii)</span> Syringes; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(b)(iii)">(iii)</span> Injection supplies; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(c)">(c)</span> When possible, cover supplies used by the participant including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(c)(i)">(i)</span> Hypodermic needles;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(c)(ii)">(ii)</span> Syringes; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#E(3)(c)(iii)">(iii)</span> Injection supplies.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F">F.</span> Needlestick Injuries.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(1)">(1)</span> OADPO programs shall implement protocols for handling needlestick injuries.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(2)">(2)</span> OADPO programs shall designate at least one needlestick manager who shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(2)(a)">(a)</span> Assist injured individuals present at the facility including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(2)(a)(i)">(i)</span> Participants;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(2)(a)(ii)">(ii)</span> Staff;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(2)(a)(iii)">(iii)</span> Volunteers; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(2)(a)(iv)">(iv)</span> Any other individuals present in an occupational capacity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(2)(b)">(b)</span> Follow established procedures for accident or incident reporting; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(2)(c)">(c)</span> Immediately notify the ranking supervisor of any needlestick injuries.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(3)">(3)</span> Participants, staff, volunteers, and any other individuals present at the facility in an occupational capacity shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(3)(a)">(a)</span> Report a needlestick injury to the on-site needlestick manager immediately; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#F(3)(b)">(b)</span> Visit the emergency room or a private physician within 24 hours of the occurrence.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#G">G.</span> Post-Exposure Management. OADPO programs shall implement protocols for post-exposure management including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#G(1)">(1)</span> Testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.06#G(2)">(2)</span> Post-exposure prophylaxis.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.01.07" data-order="|10|52|01|.07|" data-ref-path="10|52|01|.07" class="h__section">.07 Monitoring and Evaluation.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A">A.</span> OADPO programs shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)">(1)</span> Submit all data for each reporting period on a quarterly basis as required by the Department, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(a)">(a)</span> The number of:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(a)(i)">(i)</span> Participants served by the OADPO program;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(a)(ii)">(ii)</span> New participants registered by the OADPO program;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(b)">(b)</span> Demographic data of participants served by the OADPO program, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(b)(i)">(i)</span> Age;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(b)(ii)">(ii)</span> Gender identity;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(b)(iii)">(iii)</span> Sexual orientation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(b)(iv)">(iv)</span> Race;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(b)(v)">(v)</span> Ethnicity;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(b)(vi)">(vi)</span> Zip code; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(b)(vii)">(vii)</span> Types of drugs the participant reports using;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(c)">(c)</span> The number of hypodermic needles and syringes distributed and collected;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(d)">(d)</span> Each location where hypodermic needles and syringes were distributed; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(1)(e)">(e)</span> The number of referrals to services provided to participants listed in Health-General Article, §24-903(A)(6), Annotated Code of Maryland, and <a class="internal-link " href="/us/md/exec/comar/10.52.01.05#A(4)" title="">Regulation .05A(4) of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#A(2)">(2)</span> Collect data using methods that will not deter participants from utilizing OADPO program services.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.07#B">B.</span> The Department may conduct site visits to monitor and evaluate an OADPO program.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.01.08" data-order="|10|52|01|.08|" data-ref-path="10|52|01|.08" class="h__section">.08 Research.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#A">A.</span> An individual researcher or institution shall apply for and receive approval from the Department before starting research in collaboration with an OADPO program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B">B.</span> The Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(1)">(1)</span> Review each request; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)">(2)</span> Approve or disapprove the proposed research based on whether the proposed research:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)(a)">(a)</span> Advances scientific knowledge or practice related to opioid-associated disease prevention and outreach;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)(b)">(b)</span> Has approaches, aims, and methods that will allow the researcher to perform descriptive analyses or test hypotheses;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)(c)">(c)</span> Has one or more investigators who have training and experience with the approaches and methods;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)(d)">(d)</span> Will impede or interfere with the operations of the OADPO program;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)(e)">(e)</span> Is approved by the Department’s Institutional Review Board to ensure that the research will be conducted according to established ethical guidelines for research in the field of opioid-associated disease prevention and outreach; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)(f)">(f)</span> Will keep any data used for the research confidential as required by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)(f)(i)">(i)</span> Health-General Article, §24-906(B), Annotated Code of Maryland;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)(f)(ii)">(ii)</span> 42 U.S.C. §290dd-2; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.01.08#B(2)(f)(iii)">(iii)</span> 42 CFR Part 2.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.01.09" data-order="|10|52|01|.09|" data-ref-path="10|52|01|.09" class="h__section">.09 Revocation of Approval and Appeals.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#A">A.</span> The Department and the local health officer may revoke the approval of an OADPO program if the OADPO program does not:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#A(1)">(1)</span> Meet the requirements of Health-General Article, Title 24, Subtitle 9, Annotated Code of Maryland; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#A(2)">(2)</span> Operate in accordance with the requirements of Regulations .05 and .06 of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#B">B.</span> The Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#B(1)">(1)</span> Notify the OADPO program in writing of the revocation of approval; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#B(2)">(2)</span> Provide an explanation of the decision.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#C">C.</span> An OADPO program may appeal the decision to revoke approval to the Deputy Secretary for Public Health Services by submitting the request in writing to the Deputy Secretary for Public Health Services within 30 calendar days of the date postmarked on the notice of revocation of approval.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#D">D.</span> If an applicant submits an appeal, the Deputy Secretary for Public Health Services shall within 60 days:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#D(1)">(1)</span> Grant or deny the appeal; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#D(2)">(2)</span> Respond in writing to the applicant:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#D(2)(a)">(a)</span> Indicating whether the appeal has been granted or denied; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.01.09#D(2)(b)">(b)</span> Providing an explanation of the decision.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.02" data-order="|10|52|02|" data-ref-path="10|52|02" class="h__chapter">Chapter 02 High Blood Pressure Control Services</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: April 8, 1985 (12:7 Md. R. 707)</p>
                  <p>Regulation .01A, B amended effective November 20, 1994 (21:23 Md. R. 1934)</p>
                  <p>——————</p>
                  <p>Regulation .01 repealed effective October 5, 2020 (47:20 Md. R. 875)</p>
                </section>
                <h2 id="/us/md/exec/comar/10.52.03" data-order="|10|52|03|" data-ref-path="10|52|03" class="h__chapter">Chapter 03 Health Education — General Regulations</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: April 8, 1985 (12:7 Md. R. 707)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.03.01#A" title="">Regulation .01A</a>, C amended effective June 25, 2012 (39:12 Md. R. 745)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§2-104(b) and 2-105(b), Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.03.01" data-order="|10|52|03|.01|" data-ref-path="10|52|03|.01" class="h__section">.01 Health Education Services Regulations.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A">A.</span> Type of Service to Be Provided. Services to be provided are health education services of a general nature for purposes of informing the public about various health issues, promoting health enhancing behaviors, and organizing groups to promote the health enhancing activities of others or to achieve societal and environmental changes conducive to health. These services include but are not limited to the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A(1)">(1)</span> Planning, conducting, and evaluating a media campaign or a component of a media campaign;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A(2)">(2)</span> Planning, conducting, and evaluating an employee or community intervention for a specified behavior change;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A(3)">(3)</span> Training health professionals to provide effective education to their clients;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A(4)">(4)</span> Distributing existing or newly developed health-related educational materials and resources;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A(5)">(5)</span> Organizing and leading a group to find goals and strategies to achieve a health end;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A(6)">(6)</span> Implementing population-based health education programs using evidence-based methods and strategies;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A(7)">(7)</span> Assessing and analyzing community needs and assets;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A(8)">(8)</span> Accessing, interpreting, and disseminating qualitative and quantitative data; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#A(9)">(9)</span> Planning, conducting, and evaluating health promotion and education interventions and initiatives.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#B">B.</span> Client Eligibility Standards. All permanent residents of Maryland are eligible to receive services subject to the funding available and limited by the jurisdiction or jurisdictions and target populations specified in a request for proposal.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#C">C.</span> Licensing or Certification Requirements of Professional Service Providers and Facilities as Applicable.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#C(1)">(1)</span> All organizations, public and private, which are permitted to engage in business in Maryland may be contractors for health education services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#C(2)">(2)</span> If candidates seeking health educator positions in State service have similar qualifications, the Maryland Department of Health shall give a hiring preference to those candidates who have Certified Health Education Specialist (CHES) credentials issued by the National Commission for Health Education Credentialing, Inc.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.03.01#C(3)">(3)</span> Vendor requirements for specific programs, if any, will be specified in a request for proposal.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.04" data-order="|10|52|04|" data-ref-path="10|52|04" class="h__chapter">Chapter 04 Condom Vending Machines</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: November 26, 1990 (17:23 Md. R. 2733)</p>
                  <p>Chapter revised effective January 7, 2002 (28:26 Md. R. 2274)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§2-104 and 18-335; <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcr&amp;section=10-104" title="">Criminal Law Article, §10-104</a>; Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.04.01" data-order="|10|52|04|.01|" data-ref-path="10|52|04|.01" class="h__section">.01 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.04.01#A">A.</span> This chapter applies to a condom offered for sale or sold by means of a vending machine or other automatic device, and to a vending machine or other automatic device used for selling condoms.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.04.01#B">B.</span> This chapter does not apply to a condom sold person-to-person in a business establishment.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.04.02" data-order="|10|52|04|.02|" data-ref-path="10|52|04|.02" class="h__section">.02 Approved Condoms.</h3>
                <p>A condom that is approved by the U.S. Food and Drug Administration (FDA) as a medical device may be sold or offered for sale by means of a vending machine or other automatic device.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.04.03" data-order="|10|52|04|.03|" data-ref-path="10|52|04|.03" class="h__section">.03 Labeling of Product.</h3>
                <p>A novelty device which resembles a condom but is not intended for prevention of sexually transmitted diseases or pregnancy and is not FDA approved as a medical device shall be clearly marked: "This item is not intended for prevention of sexually transmitted diseases or pregnancy."</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.04.04" data-order="|10|52|04|.04|" data-ref-path="10|52|04|.04" class="h__section">.04 Labeling of Vending Machine.</h3>
                <p>A vending machine or other automatic device used for selling condoms shall be labeled with the name, address, and telephone number of the person or firm responsible for stocking the machine with condoms.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.05" data-order="|10|52|05|" data-ref-path="10|52|05" class="h__chapter">Chapter 05 Pertussis and Pertussis Vaccine</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: May 19, 1986 (13:10 Md. R. 1156)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.05.04" title=".04 Requirements of the Department.">Regulation .04</a> amended effective August 10, 2009 (36:16 Md. R. 1251)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§2-104(b)(1) and 18-332, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.05.01" data-order="|10|52|05|.01|" data-ref-path="10|52|05|.01" class="h__section">.01 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.01#A">A.</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.01#B">B.</span> "Health care provider" means any licensed health care professional, organization, or institution, whether public or private, under whose authority pertussis vaccine is administered.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.01#C">C.</span> "Major adverse reaction" means any:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.01#C(1)">(1)</span> Serious illness, disability, or impairment of mental, emotional, behavioral, or physical functioning or development, the first manifestation of which appears within 7 days after the date of administration of pertussis vaccine and for which there is reasonable scientific or medical evidence pertussis vaccine causes, or significantly contributes to, the effect; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.01#C(2)">(2)</span> Other reaction which the Department, after consultation with the Medical and Chirurgical Faculty of Maryland, determines is a basis for not continuing with pertussis vaccine administration.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.01#D">D.</span> "Patient" means the individual to whom pertussis vaccine is being administered.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.01#E">E.</span> "Pertussis vaccine" means any vaccine that contains materials intended to prevent the occurrence of pertussis, whether the materials are administered separately or in conjunction with other materials intended to prevent the occurrence of other diseases.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.05.02" data-order="|10|52|05|.02|" data-ref-path="10|52|05|.02" class="h__section">.02 Requirements for Health Care Providers.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A">A.</span> Before the administration of pertussis vaccine, the health care provider shall provide to the patient's parent or guardian written information addressing:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(1)">(1)</span> The frequency, severity, and potential long-term effects of pertussis;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(2)">(2)</span> Possible adverse reactions to pertussis vaccine, which, if they occur, should be brought to the immediate attention of the health care provider;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(3)">(3)</span> A form that lists symptoms of possible pertussis vaccine adverse reactions to be monitored and which contains places where information can be recorded to assist in reporting to the health care provider, local health officer, and the Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(4)">(4)</span> Measures parents should take to reduce the risk of, or to respond to, any major adverse reaction to pertussis vaccine;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(5)">(5)</span> Early warning signs or symptoms to which parents should be alert as possible precursors to a major adverse reaction to pertussis vaccine;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(6)">(6)</span> When and to whom parents should report any major adverse reactions to pertussis vaccine;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(7)">(7)</span> A summary of the immunization requirements adopted under <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=ged&amp;section=7-402" title="">Education Article, §7-402(a), Annotated Code of Maryland</a>, including those related to pertussis vaccine;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(8)">(8)</span> The circumstances under which pertussis vaccine may not be administered;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(9)">(9)</span> The circumstances under which administration of pertussis vaccine shall be delayed; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#A(10)">(10)</span> Categories of potential recipients who are significantly more vulnerable to major adverse reactions to pertussis vaccine than is the general population.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#B">B.</span> Before the administration of pertussis vaccine, the health care provider shall, by appropriate inquiries, attempt to elicit the information necessary to determine, based on a physician's medical judgement whether:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#B(1)">(1)</span> Pertussis vaccine should not be administered to the patient;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#B(2)">(2)</span> Administration of pertussis vaccine should be delayed; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#B(3)">(3)</span> The risk to the potential recipient of the vaccine outweighs the benefits both to the potential recipient and to the public in administering the vaccine.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#C">C.</span> The circumstances under which the administration of pertussis vaccine shall be delayed or may not occur are established by the Immunization Practices Advisory Committee (ACIP) to the Public Health Service. The Department will notify all health care providers of these circumstances.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#D">D.</span> A physician who determines, pursuant to §B, of this regulation, that the administration of the pertussis vaccine to a patient shall be delayed or may not occur shall submit to the local health officer the name, address, date of birth, and the basis for the determination for each patient.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#E">E.</span> Pertussis vaccine should not be given if in the physician's medical judgment, taking into account any categories of potential recipients who are significantly more vulnerable to major adverse reactions than is the general population, as well as all other relevant information, the risk to the potential recipient outweighs the benefits both to the potential recipient and the public in administering the vaccine.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#F">F.</span> At the time of administration of pertussis vaccine to a patient, the health care provider shall record in a permanent record to which the patient's parent or guardian shall have access upon request:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#F(1)">(1)</span> The date each dose of pertussis vaccine is administered;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#F(2)">(2)</span> The manufacturer and lot number of the vaccine used for each;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#F(3)">(3)</span> Other identifying information on the vaccine used; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#F(4)">(4)</span> The name and title of the health care provider who authorized the vaccine to be administered and the one who administered it.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#G">G.</span> A health care provider who has administered the pertussis vaccine to a patient and who has been informed by the parent or guardian of the patient, or has reason to believe that the patient has had a major adverse reaction to pertussis vaccine, shall within 24 hours of receipt of that knowledge:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#G(1)">(1)</span> Record to the extent of his knowledge all relevant information in the patient's permanent medical record; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.02#G(2)">(2)</span> Report information, including the manufacturer's name, date of administration, type and lot number of the vaccine, a brief description of the reaction, and other specified information on a morbidity report card, to the local health officer. These reports can also be made by telephone.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.05.03" data-order="|10|52|05|.03|" data-ref-path="10|52|05|.03" class="h__section">.03 Requirements of Local Health Officers.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.03#A">A.</span> Upon receipt of notification of a major adverse reaction to a pertussis vaccine, the local health officer shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.03#A(1)">(1)</span> Notify and forward the morbidity report card to the Department within 24 hours; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.03#A(2)">(2)</span> Assure that the necessary information to fill out a "Report of Adverse Event Following Immunization" is obtained.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.03#B">B.</span> At the time of completion, the report shall be submitted to the Department.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.05.04" data-order="|10|52|05|.04|" data-ref-path="10|52|05|.04" class="h__section">.04 Requirements of the Department.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#A">A.</span> Whenever a resident birth occurs, the Department shall promptly provide parents of the newborn child with information included in Regulation .02A(1)—(10) of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#B">B.</span> The Department shall prescribe the form and content of the information about immunizations provided to parents at times of birth and of administration of pertussis vaccine, according to Regulation .02A(1)—(10) of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#C">C.</span> Upon receipt of information regarding a major adverse reaction to a pertussis vaccine, the Department shall immediately notify the vaccine manufacturer of the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#C(1)">(1)</span> Date of immunization;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#C(2)">(2)</span> Lot number of vaccine; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#C(3)">(3)</span> Type of reaction.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#D">D.</span> The Department shall establish a system to collect data from local health officers, from public and private health care providers, and from parents, on the incidence of pertussis and major adverse reactions to pertussis vaccine. This system shall be organized so that periodic revisions and updates of information and guidelines may be made. In addition, the information collected shall be sufficient for any reports required by the Department on pertussis and major adverse reactions to pertussis vaccine.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#E">E.</span> On the basis of the data collected and of any other information available, the Department shall periodically revise and update:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#E(1)">(1)</span> The information provided to parents at the times of birth and of administration of pertussis vaccine;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#E(2)">(2)</span> The information provided to health care providers regarding pertussis immunization deferral or exemption, and all other information otherwise regarding risks and benefits to the patient and to the public; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#E(3)">(3)</span> Other pertinent information on pertussis and pertussis vaccine</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#F">F.</span> The Department shall report to the Centers for Disease Control (CDC) the incidence of pertussis and major adverse reactions to pertussis vaccine.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.05.04#G">G.</span> The Department shall notify by mail or other means, or both, all health care providers of their responsibilities relevant to these regulations as well as other appropriate materials (for example, ACIP recommendations, parent information pamphlets, and morbidity report cards). Revisions of these and new materials shall also be distributed in the same manner.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.05.05" data-order="|10|52|05|.05|" data-ref-path="10|52|05|.05" class="h__section">.05 General.</h3>
                <p>Nothing in these regulations shall be construed to affect any emergency authority of the Secretary of Health and under any other provision of law to protect the public health.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.06" data-order="|10|52|06|" data-ref-path="10|52|06" class="h__chapter">Chapter 06 Use of Tanning Devices by Minors</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: June 29, 2009 (36:13 Md. R. 900)</p>
                  <p>Regulation .12B amended effective March 14, 2016 (43:5 Md. R. 385)</p>
                  <p>——————</p>
                  <p>Chapter revised effective October 5, 2020 (47:20 Md. R. 875)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §20-106, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.06.01" data-order="|10|52|06|.01|" data-ref-path="10|52|06|.01" class="h__section">.01 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.01#A">A.</span> This chapter establishes regulations on the use of tanning devices by minors.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.01#B">B.</span> Nothing in this chapter preempts a county or municipal government from enacting and enforcing more stringent measures to regulate the use of tanning devices by minors.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.06.02" data-order="|10|52|06|.02|" data-ref-path="10|52|06|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(1)">(1)</span> “Customer” means a member of the public who is provided access to a tanning device in exchange for a fee, membership dues, or other compensation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(2)">(2)</span> “Department” means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(3)">(3)</span> “Health officer” means the health officer of each of the 23 counties in Maryland and the Commissioner of Health in Baltimore City, the duly designated representative of the health officer, or both.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(4)">(4)</span> “Minor” means an individual younger than 18 years old.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(5)">(5)</span> “Owner” means an individual or entity having an ownership interest in a tanning facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(6)">(6)</span> “Person-in-charge” means an owner, operator, manager, employee, or other individual who controls, governs, or directs the activities of a tanning facility and is present on site.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(7)">(7)</span> “Phototherapy device” means any equipment that emits ultraviolet radiation and is used in the diagnosis or treatment of disease or injury.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(8)">(8)</span> “Radiation” means ultraviolet radiation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(9)">(9)</span> “Secretary” means the Secretary of Health or the Secretary's designee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(10)">(10)</span> “Tanning device” means any equipment that emits radiation used for tanning of the skin, including sunlamps, tanning booths, or tanning beds.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.02#B(11)">(11)</span> “Tanning facility” means any place where a tanning device is used for a fee, membership dues, or other compensation.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.06.03" data-order="|10|52|06|.03|" data-ref-path="10|52|06|.03" class="h__section">.03 Exclusions.</h3>
                <p>This chapter does not apply to the use of any phototherapy device by a health care practitioner acting within the scope of the license of the health care practitioner or by order of a health care practitioner acting within the scope of the license of the health care practitioner.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.06.04" data-order="|10|52|06|.04|" data-ref-path="10|52|06|.04" class="h__section">.04 Verification of Age.</h3>
                <p>A person-in-charge may not allow a customer to use a tanning device at a tanning facility without confirmation, with a State or federal government-issued identification card, that the individual is not a minor.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.06.05" data-order="|10|52|06|.05|" data-ref-path="10|52|06|.05" class="h__section">.05 Posting of Notices.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#A">A.</span> A tanning facility shall display conspicuously a notice that conforms to the requirements of <a class="internal-link " href="/us/md/exec/comar/10.52.06.05#B" title="">§B of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#B">B.</span> The notice shall state:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#B(1)">(1)</span> That it is unlawful for a tanning facility owner, employee, or operator to allow a minor to use any tanning device;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#B(2)">(2)</span> That a tanning facility owner, employee, or operator that violates one or more provisions of this section may be subject to a civil penalty;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#B(3)">(3)</span> The health risks associated with tanning, including skin cancer, premature skin aging, injuries including burns, and adverse reactions when combined with certain medications, foods, and cosmetics; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#B(4)">(4)</span> That an individual may report a violation of one or more provisions of this chapter to the local law enforcement agency or local health department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#C">C.</span> The notice shall be:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#C(1)">(1)</span> Readily visible and at least 18-point type font; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#C(2)">(2)</span> Made available to a tanning facility by the Department on the Department’s website.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.05#D">D.</span> The owner or person-in-charge shall ensure that the notice required under this regulation is conspicuously posted and in good condition.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.06.06" data-order="|10|52|06|.06|" data-ref-path="10|52|06|.06" class="h__section">.06 Complaints and Investigations.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.06#A">A.</span> A person or law enforcement officer may report a violation of this chapter to the health officer in the jurisdiction where the alleged violation took place.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.06#B">B.</span> The Department shall make available a complaint form at the Department's website and at a local health department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.06#C">C.</span> Upon receipt of a complaint, the health officer shall investigate the complaint.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.06.07" data-order="|10|52|06|.07|" data-ref-path="10|52|06|.07" class="h__section">.07 Enforcement.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.07#A">A.</span> A health officer may investigate conditions relative to the enforcement of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.07#B">B.</span> The person-in-charge of a tanning facility shall permit a health officer to enter the tanning facility during business hours for the purpose of determining compliance with this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.07#C">C.</span> If an investigation is made, the health officer shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.07#C(1)">(1)</span> Document:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.06.07#C(1)(a)">(a)</span> The result of the investigation on a report form provided by the Department; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.06.07#C(1)(b)">(b)</span> A condition found that is in violation of a provision of this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.07#C(2)">(2)</span> Furnish one copy of the report form to the person-in-charge of the tanning facility; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.07#C(3)">(3)</span> Make the completed report form available for public disclosure in accordance with the Maryland Public Information Act, State Government Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gsg&amp;section=10-611" title="">10-611</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gsg&amp;section=10-628" title="">10-628</a>, Annotated Code of Maryland.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.06.08" data-order="|10|52|06|.08|" data-ref-path="10|52|06|.08" class="h__section">.08 Violations and Certification of Correction.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.08#A">A.</span> The health officer shall provide the owner of a tanning facility found in violation of a provision of this chapter or Health-General Article, §20-106, Annotated Code of Maryland, with a written notice that contains:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.08#A(1)">(1)</span> The specific finding and, if applicable, the penalty for the violation, as set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.06.09" title=".09 Penalties.">Regulation .09 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.08#A(2)">(2)</span> A specific date by which the owner shall correct the violation;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.08#A(3)">(3)</span> A provision that, if the owner fails to correct the violation by the date specified or is in violation of another provision of Health-General Article, §20-106, Annotated Code of Maryland, at another time, the Secretary may impose a subsequent penalty, if applicable, as set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.06.09" title=".09 Penalties.">Regulation .09 of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.08#A(4)">(4)</span> A provision that the owner is entitled to request a hearing under <a class="internal-link " href="/us/md/exec/comar/10.52.06.10" title=".10 Request for Hearing.">Regulation .10 of this chapter</a> on a violation with a penalty.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.08#B">B.</span> The owner of a tanning facility shall submit to the health officer a written certification of correction within a time frame provided by the local health department that states:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.08#B(1)">(1)</span> The violation; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.08#B(2)">(2)</span> How the violation was corrected.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.06.09" data-order="|10|52|06|.09|" data-ref-path="10|52|06|.09" class="h__section">.09 Penalties.</h3>
                <p>The penalties for a violation of Regulation .04 or .05 of this chapter, or of Health-General Article, §20-106, Annotated Code of Maryland, are:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.09#A">A.</span> A letter of reprimand for the first violation;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.09#B">B.</span> A civil penalty of $250 for a second violation;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.09#C">C.</span> A civil penalty of $500 for a third violation; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.09#D">D.</span> A civil penalty of $1,000 for each subsequent violation.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.06.10" data-order="|10|52|06|.10|" data-ref-path="10|52|06|.10" class="h__section">.10 Request for Hearing.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.10#A">A.</span> A person who receives a notice of violation with a penalty for a violation of Regulation .04, .05C, D, or E, or .06 of this chapter, or of Health-General Article, §20-106, Annotated Code of Maryland, may request a hearing on the notice of violation with a penalty.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.10#B">B.</span> In order to preserve a right to a hearing on a violation with a penalty under this chapter, if a hearing is desired, a person shall submit a written request to the Department’s Environmental Health Bureau under the Prevention and Health Promotion Administration for a hearing within 10 days of receipt of the notice of violation with a penalty.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.10#C">C.</span> In accordance with the Administrative Procedure Act, <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gsg/gsg.pdf" title="">State Government Article, Title 10, Subtitle 2, Annotated Code of Maryland</a>, the Secretary shall provide for a hearing on the violation with a penalty by referring the matter to the Office of Administrative Hearings.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.06.10#D">D.</span> The Office of Administrative Hearings shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.10#D(1)">(1)</span> Schedule and conduct the hearing on the violation with a penalty; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.06.10#D(2)">(2)</span> Render a decision and notify the parties of the decision within 90 days after the hearing.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.07" data-order="|10|52|07|" data-ref-path="10|52|07" class="h__chapter">Chapter 07 State Advisory Council on Health and Wellness</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: January 29, 2018 (45:2 Md. R. 69)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§13-201—13-206, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.07.01" data-order="|10|52|07|.01|" data-ref-path="10|52|07|.01" class="h__section">.01 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(1)">(1)</span> “Chronic disease” means a noncommunicable condition that is a major cause of sickness or disability, including, but not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(1)(a)">(a)</span> Heart disease;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(1)(b)">(b)</span> Cancer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(1)(c)">(c)</span> Arthritis; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(1)(d)">(d)</span> Diabetes.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(2)">(2)</span> “Council” means the State Advisory Council on Health and Wellness established by Health-General Article, §13-202, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(3)">(3)</span> “Evidence-based program” means a program that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(3)(a)">(a)</span> Engages the community in assessment and decision making;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(3)(b)">(b)</span> Uses data and information systems to inform program activities;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(3)(c)">(c)</span> Is based on peer-reviewed evidence;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(3)(d)">(d)</span> Uses program-planning frame works;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(3)(e)">(e)</span> Conducts evaluation; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(3)(f)">(f)</span> Disseminates the results of the evaluation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(4)">(4)</span> “Healthy lifestyle” means behaviors that promote wellness and prevent disease including, but not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(4)(a)">(a)</span> Maintaining a healthy weight;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(4)(b)">(b)</span> Engaging in regular physical activity;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(4)(c)">(c)</span> Refraining from smoking;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(4)(d)">(d)</span> Limiting consumption of alcohol;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(4)(e)">(e)</span> Reducing stress; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(4)(f)">(f)</span> Getting sufficient sleep.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(5)">(5)</span> “Quorum” means a majority of the full membership of the Council or of a committee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.01#B(6)">(6)</span> “Secretary” means the Secretary of Health.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.07.02" data-order="|10|52|07|.02|" data-ref-path="10|52|07|.02" class="h__section">.02 Membership.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#A">A.</span> The Council shall consist of 34 members appointed by the Secretary according to Health-General Article, §13-203, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#B">B.</span> A member shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#B(1)">(1)</span> Be a Maryland resident; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#B(2)">(2)</span> If a qualified Maryland resident is not available to be appointed to a Council position, possess special knowledge or training required for the Council position to which they are appointed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#C">C.</span> A member that is subject to term limits:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#C(1)">(1)</span> Shall serve a 4-year term;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#C(2)">(2)</span> May serve two consecutive full terms;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#C(3)">(3)</span> At the end of a term, shall continue to serve until a successor is appointed and qualifies;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#C(4)">(4)</span> If appointed after a term has begun, shall only serve for the rest of the term and until a successor is appointed and qualifies; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#C(5)">(5)</span> May not be reappointed to the Council for 4 years after serving two consecutive full terms.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#D">D.</span> Members shall serve on at least one committee.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#E">E.</span> The Council Chair shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#E(1)">(1)</span> Be appointed by the Secretary;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#E(2)">(2)</span> Serve a 2-year term;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#E(3)">(3)</span> Be allowed to serve two consecutive terms; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.02#E(4)">(4)</span> Appoint the Chairs of the committees.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.07.03" data-order="|10|52|07|.03|" data-ref-path="10|52|07|.03" class="h__section">.03 Committees.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.03#A">A.</span> The Council shall have the following four committees:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.03#A(1)">(1)</span> Arthritis;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.03#A(2)">(2)</span> Diabetes;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.03#A(3)">(3)</span> Heart Disease and Stroke; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.03#A(4)">(4)</span> Physical Fitness.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.03#B">B.</span> The Council may create:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.03#B(1)">(1)</span> Additional committees to organize the Council’s work; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.03#B(2)">(2)</span> Temporary ad hoc committees to accomplish a specific task.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.03#C">C.</span> Except for the committees created according to <a class="internal-link " href="/us/md/exec/comar/10.52.07.03#A" title="">§A of this regulation</a>, the Council may dissolve a committee at any time.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.07.04" data-order="|10|52|07|.04|" data-ref-path="10|52|07|.04" class="h__section">.04 Council Duties.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.04#A">A.</span> The Council shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.04#A(1)">(1)</span> Provide guidance to the Secretary on Statewide chronic disease prevention and control;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.04#A(2)">(2)</span> Direct the priorities and work of the committees; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.04#A(3)">(3)</span> Promote evidence-based programs for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.04#A(3)(a)">(a)</span> Healthy lifestyles; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.04#A(3)(b)">(b)</span> The prevention, early detection, and treatment of chronic disease.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.04#B">B.</span> The Council shall submit a report of its activities to the Secretary on or before December 31, 2019 and every 2 years thereafter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.07.05" data-order="|10|52|07|.05|" data-ref-path="10|52|07|.05" class="h__section">.05 Meetings and Procedures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#A">A.</span> Meeting Frequency.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#A(1)">(1)</span> The Council shall meet at least two times per year.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#A(2)">(2)</span> A committee created by <a class="internal-link " href="/us/md/exec/comar/10.52.07.03#A" title="">Regulation .03A of this chapter</a> shall meet at least four times per year.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#B">B.</span> Quorum.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#B(1)">(1)</span> A quorum shall be present to conduct a Council or committee vote.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#B(2)">(2)</span> If a quorum is not present:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#B(2)(a)">(a)</span> A meeting may still be held; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#B(2)(b)">(b)</span> An activity requiring a vote shall be deferred to the next meeting with a quorum present.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#C">C.</span> Voting.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#C(1)">(1)</span> A member shall have one vote.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#C(2)">(2)</span> Voting shall be:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#C(2)(a)">(a)</span> In person; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#C(2)(b)">(b)</span> By phone.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D">D.</span> Attendance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(1)">(1)</span> A member shall attend at least:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(1)(a)">(a)</span> 50 percent of the Council meetings per year; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(1)(b)">(b)</span> 75 percent of the meetings of a committee on which the member serves per year.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(2)">(2)</span> The Council shall ensure that attendance is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(2)(a)">(a)</span> Recorded in the meeting minutes; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(2)(b)">(b)</span> Submitted to the Secretary at least once per year.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(3)">(3)</span> The Secretary may remove a member for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(3)(a)">(a)</span> Neglect of duty;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(3)(b)">(b)</span> Incompetence;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(3)(c)">(c)</span> Misconduct;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(3)(d)">(d)</span> Malfeasance;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(3)(e)">(e)</span> Misfeasance in office; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.07.05#D(3)(f)">(f)</span> Failing to meet the requirements of <a class="internal-link " href="/us/md/exec/comar/10.52.07.05#D(1)" title="">§D(1) of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.08" data-order="|10|52|08|" data-ref-path="10|52|08" class="h__chapter">Chapter 08 Maryland HIV Prevention Case Management Program</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: May 20, 2019 (46:10 Md. R. 490)</p>
                  <p>——————</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.08.01" title=".01 Scope and Purpose.">.01</a>—.16 under Maryland HIV Prevention Case Management Program repealed and new Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.08.01" title=".01 Scope and Purpose.">.01</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.08.05" title=".05 Eligibility Criteria.">.05</a> under Maryland AIDS Drug Assistance Program Fund adopted effective December 25, 2023 (50:25 Md. R. 1088)</p>
                  <h3>Authority</h3>
                  <p>: Health-General Article, §24-1801, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.08.01" data-order="|10|52|08|.01|" data-ref-path="10|52|08|.01" class="h__section">.01 Scope and Purpose.</h3>
                <p>This chapter:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.01#A">A.</span> Defines the Maryland AIDS Drug Assistance Program Fund;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.01#B">B.</span> Sets forth the responsibilities of the Maryland Department of Health with respect to the Maryland AIDS Drug Assistance Program Fund; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.01#C">C.</span> Establishes eligibility criteria for receipt of HIV prevention and care services from the Fund.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.08.02" data-order="|10|52|08|.02|" data-ref-path="10|52|08|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.02#B(1)">(1)</span> “Acquired immunodeficiency syndrome (AIDS)” means the medical condition caused by the human immunodeficiency virus.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.02#B(2)">(2)</span> “Department” means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.02#B(3)">(3)</span> "Fund" means the Maryland AIDS Assistance Program Fund.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.02#B(4)">(4)</span> “Human immunodeficiency virus (HIV)” means the virus that causes AIDS.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.02#B(5)">(5)</span> “Ryan White HIV/AIDS Program (RWHAP)” means the federal HIV/AIDS initiative administered by the U.S. Department of Health and Human Services (HHS), Health Resources and Services Administration (HRSA), HIV/AIDS Bureau (HAB).</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.08.03" data-order="|10|52|08|.03|" data-ref-path="10|52|08|.03" class="h__section">.03 Maryland AIDS Drug Assistance Program Fund.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#A">A.</span> The Maryland AIDS Drug Assistance Program Fund is a nonlapsing, special fund created by Health-General Article, §24-1801, Annotated Code of Maryland, for HIV treatment and care, which is generated from:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#A(1)">(1)</span> The 340B Drug Pricing Program and any supplemental rebate dollars; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#A(2)">(2)</span> Interest earned on the balance of the Fund.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#B">B.</span> The Department may only expend funds in accordance with Title 26 of the Public Health Service Act governing the allowable uses of RWHAP funds or to meet State-identified HIV priorities.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#C">C.</span> The Department may make grant awards under the Fund.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#D">D.</span> Any unspent portions of the Fund shall remain in the Fund and may not revert to the General Fund of the State.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#E">E.</span> Money expended from the Fund is additive to, and is not intended to take the place of, funding that would otherwise be appropriated to the Department for HIV:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#E(1)">(1)</span> Surveillance;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#E(2)">(2)</span> Prevention;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#E(3)">(3)</span> Treatment; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.03#E(4)">(4)</span> Care.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.08.04" data-order="|10|52|08|.04|" data-ref-path="10|52|08|.04" class="h__section">.04 Responsibilities of the Department.</h3>
                <p>The Department:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.04#A">A.</span> Shall administer the Fund; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.04#B">B.</span> May spend the Fund on statutorily permitted purposes under the RWHAP or State-identified HIV priorities.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.08.05" data-order="|10|52|08|.05|" data-ref-path="10|52|08|.05" class="h__section">.05 Eligibility Criteria.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.05#A">A.</span> The Fund shall be the reasonable payor of last resort for receipt of HIV prevention and care services; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.08.05#B">B.</span> Eligible individuals shall have exhausted all other potential payors, including but not limited to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.05#B(1)">(1)</span> Third-party insurance;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.05#B(2)">(2)</span> Medicaid; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.08.05#B(3)">(3)</span> Medicare.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.09" data-order="|10|52|09|" data-ref-path="10|52|09" class="h__chapter">Chapter 09 HIV/CD4+ Lymphocyte Count Reporting by Unique Patient Identifying Number</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: June 1, 1994 (21:8 Md. R. 674)</p>
                  <p>Regulation .01C amended effective April 21, 1997 (24:8 Md. R. 616)</p>
                  <p>Regulation .01-1 adopted effective April 21, 1997 (24:8 Md. R. 616)</p>
                  <p>Regulation .02B amended effective April 21, 1997 (24:8 Md. R. 616)</p>
                  <p>Regulation .03A amended as an emergency provision effective June 16, 1998 (25:14 Md. R. 1128); amended permanently effective September 21, 1998 (25:19 Md. R. 1496)</p>
                  <p>——————</p>
                  <p>Chapter repealed effective February 18, 2002 (29:3 Md. R. 220)</p>
                </section>
                <h2 id="/us/md/exec/comar/10.52.10" data-order="|10|52|10|" data-ref-path="10|52|10" class="h__chapter">Chapter 10 HIV and Hepatitis C Testing of Persons Accused or Convicted, or Both, of Certain Crimes</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: December 20, 1993 (20:25 Md. R. 1948)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.10.01" title=".01 Scope.">Regulation .01</a> amended effective May 7, 2018 (45:9 Md. R. 462)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.10.02#B" title="">Regulation .02B</a> amended effective May 7, 2018 (45:9 Md. R. 462)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.10.03#A" title="">Regulation .03A</a>, E amended effective May 7, 2018 (45:9 Md. R. 462)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.10.05" title=".05 Testing of Offender.">Regulation .05</a> amended effective May 7, 2018 (45:9 Md. R. 462)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.10.06" title=".06 Information for the Victim.">Regulation .06</a> amended effective May 7, 2018 (45:9 Md. R. 462)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.10.07" title=".07 Confidentiality.">Regulation .07</a> amended effective May 7, 2018 (45:9 Md. R. 462)</p>
                  <h3>Authority</h3>
                  <p>Criminal Procedure Article §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.10.01" data-order="|10|52|10|.01|" data-ref-path="10|52|10|.01" class="h__section">.01 Scope.</h3>
                <p>This chapter establishes procedures for HIV and hepatitis C testing ordered under the provisions of Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.10.02" data-order="|10|52|10|.02|" data-ref-path="10|52|10|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(1)">(1)</span> "County" means Baltimore City or a Maryland county.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(2)">(2)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(3)">(3)</span> Exposure.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(3)(a)">(a)</span> “Exposure” means one of the following:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(3)(a)(i)">(i)</span> Percutaneous contact of a victim with blood or body fluids of an offender;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(3)(a)(ii)">(ii)</span> Mucocutaneous contact of a victim with blood or body fluids of an offender;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(3)(a)(iii)">(iii)</span> Open wound, including dermatitis, exudative lesions, or chapped skin, contact of a victim with blood or body fluids of an offender for a prolonged period; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(3)(a)(iv)">(iv)</span> Intact skin contact of a victim with large amounts of blood or body fluids of an offender for a prolonged period.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(3)(b)">(b)</span> “Exposure” includes a prohibited exposure as defined by <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">Criminal Procedure Article, §11-107(e), Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(4)">(4)</span> “Health officer” means the Baltimore City Commissioner of Health or the health officer of a county.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(5)">(5)</span> "HIV" means a human immunodeficiency virus that causes acquired immune deficiency syndrome.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(6)">(6)</span> "Intact skin contact of a victim with large amounts of blood or body fluids of an offender for a prolonged period" means that a large volume of blood or bloody body fluid of an offender has been in direct contact with unbroken skin of a victim for at least 60 minutes.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(7)">(7)</span> “Local health department” means the official public health agency in Baltimore City or a Maryland county.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(8)">(8)</span> "Mucocutaneous contact of a victim with blood or body fluids of an offender" means that blood or bloody body fluid of an offender has splashed into the eye, mouth, or nose of a victim.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(9)">(9)</span> "Offender" means one of the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(9)(a)">(a)</span> An individual convicted of an offense and ordered by a court to furnish a sample to be tested for the presence of HIV or hepatitis C under Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(9)(b)">(b)</span> An individual being granted probation before judgment and ordered by a court to furnish a sample to be tested for the presence of HIV or hepatitis C under Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(9)(c)">(c)</span> An individual charged with an offense and ordered by a court to furnish a sample to be tested for the presence of HIV or hepatitis C under Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(10)">(10)</span> “Offense” means any criminal offense or delinquent act the commission of which may have caused or resulted in an exposure.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(11)">(11)</span> "Open wound contact of a victim with blood or body fluids of an offender for a prolonged period" means that blood or bloody body fluid of an offender has contacted an already existing open wound, sore, or chapped or non-intact skin of a victim for at least 5 minutes.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(12)">(12)</span> "Percutaneous contact of a victim with blood or body fluids of an offender" means that a sharp object has penetrated the skin of a victim and allowed the blood or bloody body fluid of an offender to enter the victim's body.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(13)">(13)</span> Residence.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(13)(a)">(a)</span> "Residence" means the location where an individual normally resides.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(13)(b)">(b)</span> "Residence" includes a facility where an offender is incarcerated, operated by the Department of Public Safety and Correctional Services or a Maryland county.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(14)">(14)</span> “Secretary” means the Secretary of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(15)">(15)</span> Victim.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(15)(a)">(a)</span> "Victim" means an individual, other than the offender, injured during the commission of an offense.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(15)(b)">(b)</span> “Victim” includes the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(15)(b)(i)">(i)</span> Parent of a victim who is a minor;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(15)(b)(ii)">(ii)</span> Legal guardian of a victim;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(15)(b)(iii)">(iii)</span> Individual authorized to give surrogate consent for the victim under Health-General Article, §5-605, Annotated Code of Maryland; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.10.02#B(15)(b)(iv)">(iv)</span> Victim as defined by <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">Criminal Procedure Article, §11-107(f), Annotated Code of Maryland</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.10.03" data-order="|10|52|10|.03|" data-ref-path="10|52|10|.03" class="h__section">.03 Notice.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#A">A.</span> The health officer shall require receipt of a written notice and a copy of a court order for testing from a State’s Attorney before initiating the process of HIV or hepatitis C testing and notification described in this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#B">B.</span> The State's Attorney shall include all of the following in the written notice:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#B(1)">(1)</span> The name of the offender to be tested;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#B(2)">(2)</span> The address of the offender's residence;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#B(3)">(3)</span> The name of the victim who has requested information; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#B(4)">(4)</span> The address of the victim's residence.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#C">C.</span> If the current residence of the offender is outside of the county or counties served by the health officer who receives the notification described in <a class="internal-link " href="/us/md/exec/comar/10.52.10.03#A" title="">§A of this regulation</a>, the health officer shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#C(1)">(1)</span> Send a copy of the written notice and a copy of the court order for testing to the health officer of the county in which the offender resides; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#C(2)">(2)</span> Request the assistance of the health officer of the county in which the offender resides in carrying out the requirements of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#D">D.</span> If the current residence of the victim is in Maryland but outside of the county or counties served by the health officer who receives the notification described in <a class="internal-link " href="/us/md/exec/comar/10.52.10.03#A" title="">§A of this regulation</a>, the health officer shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#D(1)">(1)</span> Send a copy of the written notice and a copy of the court order for testing to the health officer of the county where the victim resides; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#D(2)">(2)</span> Request assistance with carrying out the requirements of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#E">E.</span> If the current residence of the victim is outside of Maryland, the health officer who receives the notification described in <a class="internal-link " href="/us/md/exec/comar/10.52.10.03#A" title="">§A of this regulation</a> shall send a letter to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#E(1)">(1)</span> The state health department of the state in which the victim resides, requesting assistance with providing appropriate services to the victim; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#E(2)">(2)</span> The victim, explaining that the victim may do one of the following to obtain information about the offender’s HIV or hepatitis C test result:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#E(2)(a)">(a)</span> Contact the state health department in the state where the victim resides; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.03#E(2)(b)">(b)</span> Contact the local health department notified under <a class="internal-link " href="/us/md/exec/comar/10.52.10.03#A" title="">§A of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.10.04" data-order="|10|52|10|.04|" data-ref-path="10|52|10|.04" class="h__section">.04 Responsibility.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.04#A">A.</span> The health officer of the county in which the offender currently resides shall assume responsibility for carrying out the activities described in <a class="internal-link " href="/us/md/exec/comar/10.52.10.05" title=".05 Testing of Offender.">Regulation .05 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.04#B">B.</span> The health officer of the county in which the victim currently resides shall assume responsibility for carrying out the activities described in <a class="internal-link " href="/us/md/exec/comar/10.52.10.06" title=".06 Information for the Victim.">Regulation .06 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.04#C">C.</span> If the current residence of the victim is outside of Maryland, the health officer notified under <a class="internal-link " href="/us/md/exec/comar/10.52.10.03#A" title="">Regulation .03A of this chapter</a> shall assume responsibility for carrying out the activities described in <a class="internal-link " href="/us/md/exec/comar/10.52.10.06" title=".06 Information for the Victim.">Regulation .06 of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.10.05" data-order="|10|52|10|.05|" data-ref-path="10|52|10|.05" class="h__section">.05 Testing of Offender.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A">A.</span> HIV and Hepatitis C Testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(1)">(1)</span> Specimen Collection.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(1)(a)">(a)</span> A specimen shall be collected from an offender following the methods described in the specifications for the blood or oral fluid test used.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(1)(b)">(b)</span> The local health department shall provide guidance on how specimens shall be collected.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(2)">(2)</span> If the offender is incarcerated in a facility under the jurisdiction of the Department of Public Safety and Correctional Services, HIV and hepatitis C testing of the offender may be performed by an employee or contractor of either the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(2)(a)">(a)</span> Local health department; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(2)(b)">(b)</span> Department of Public Safety and Correctional Services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(3)">(3)</span> If the offender is incarcerated in a facility under the jurisdiction of the county, HIV and hepatitis C testing may be performed by an employee or contractor of either the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(3)(a)">(a)</span> Local health department; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(3)(b)">(b)</span> County.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#A(4)">(4)</span> If the offender is not incarcerated, an employee or contractor of the local health department shall perform HIV and hepatitis C testing of the offender.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#B">B.</span> The health officer shall send a certified letter, accompanied by a copy of the court order for testing, to each offender who is not incarcerated, to notify the offender of all of the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#B(1)">(1)</span> That the health officer has been instructed by the court to perform an HIV or hepatitis C test on the offender; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#B(2)">(2)</span> That the offender has been scheduled for a test at a specified date, time, and place.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#C">C.</span> The health officer or designee shall do all of the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#C(1)">(1)</span> Conduct a face-to-face discussion with the offender before a sample is collected for an HIV or hepatitis C test;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#C(2)">(2)</span> Include all of the topics described in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.06" title=".06 Consent and Pretest Requirements for HIV Testing by Health Care Providers.">COMAR 10.18.08.06</a> regarding the offender’s HIV test in the discussion; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#C(3)">(3)</span> Sign a form indicating that the health officer or designee offered information to the offender on the HIV or hepatitis C test.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#D">D.</span> Blood Drawing and Testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#D(1)">(1)</span> The health officer may not use the result of a previous HIV or hepatitis C test instead of conducting an HIV or hepatitis C test required under the provisions of Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#D(2)">(2)</span> The health officer may not use a sample taken for another purpose instead of obtaining a sample in order to conduct an HIV or hepatitis C test required under Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#D(3)">(3)</span> The health officer or designee shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#D(3)(a)">(a)</span> Obtain a sample from the offender;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#D(3)(b)">(b)</span> Put the code "RP" on the blood sample and the test order; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#D(3)(c)">(c)</span> Send the sample to the Laboratories Administration within the Department for an HIV or hepatitis C test.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#E">E.</span> Upon receipt of the test result of the offender, the health officer or designee shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#E(1)">(1)</span> Discuss the result with the offender; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#E(2)">(2)</span> Transmit the test result to the individual designated by the health officer to provide post-test information, including the topics listed in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08" title="Chapter 08 HIV Testing Procedures">COMAR 10.18.08</a> that are applicable to the HIV test result.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#F">F.</span> Charges. The local health department shall charge the offender for the expenses incurred in carrying out the responsibilities outlined in this regulation if the court has ordered the defendant to make restitution for expenses incurred by the Department under Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#G">G.</span> State’s Attorney Notification. The health officer shall notify the State’s Attorney who transmitted the victim’s request for an HIV or hepatitis C test when one or more of the following actions occurs:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#G(1)">(1)</span> HIV or hepatitis C testing of an offender, including pretest and post-test information, is completed;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#G(2)">(2)</span> An offender refuses to allow a sample to be taken for testing;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#G(3)">(3)</span> An offender ordered by the court to make restitution for expenses incurred by the Department refuses to pay the required amount; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.05#G(4)">(4)</span> An offender who is not incarcerated fails to appear for HIV or hepatitis C testing.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.10.06" data-order="|10|52|10|.06|" data-ref-path="10|52|10|.06" class="h__section">.06 Information for the Victim.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#A">A.</span> The health officer or designee shall provide the victim with information addressing all of the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#A(1)">(1)</span> An explanation of HIV, AIDS, and hepatitis C;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#A(2)">(2)</span> An explanation of the risks of HIV and hepatitis C transmission in the course of a sexual or other offense;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#A(3)">(3)</span> The advisability of HIV and hepatitis C testing of the victim;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#A(4)">(4)</span> The advisability of the victim taking precautions to prevent the spread of HIV and hepatitis C until it is certain that the victim is not infected;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#A(5)">(5)</span> The advisability of the victim starting post-exposure prophylaxis prior to receiving test results; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#A(6)">(6)</span> The HIV and hepatitis C test result of the offender.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#B">B.</span> If the HIV or hepatitis C test result of the offender is positive, the health officer or designee shall offer, provide, or arrange for appropriate HIV or hepatitis C services, including referral for appropriate health care and support services, for the victim.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#C">C.</span> If the HIV test result of the offender is indeterminate, the health officer or designee of the health officer shall inform the victim about the advisability of requesting the court to order a second HIV test 8 to 12 weeks after the first test to determine whether the test result has changed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.06#D">D.</span> The health officer or designee shall inform the victim about the requirements for confidentiality of information relating to the HIV or hepatitis C test result of the offender, as specified in Regulation .07C and D of this chapter.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.10.07" data-order="|10|52|10|.07|" data-ref-path="10|52|10|.07" class="h__section">.07 Confidentiality.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#A">A.</span> Local Health Department Records. The local health department shall maintain separate confidential records of information and test results given to an offender required under the provisions of Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#B">B.</span> Disclosure by Health Officer or Designee.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#B(1)">(1)</span> Except as provided in Regulations .05E and .06A(6) of this chapter and as otherwise provided by law, the health officer or designee may not disclose the HIV or hepatitis C result of the offender.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#B(2)">(2)</span> The health officer or designee may not place the HIV or hepatitis C test result of the offender in any record relating to the offender maintained within a facility in which the offender is incarcerated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#C">C.</span> Disclosure by Victim. The victim may not disclose the offender's test result to any individual unless the disclosure is necessary to protect the health and safety of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#C(1)">(1)</span> The victim;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#C(2)">(2)</span> The victim's sexual partner; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#C(3)">(3)</span> The victim's family.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#D">D.</span> Redisclosure. An individual notified of the result of an HIV or hepatitis C test performed under provisions of this chapter may not disclose the information except to protect the health and safety of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#D(1)">(1)</span> The victim;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#D(2)">(2)</span> The victim's sexual partner; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.10.07#D(3)">(3)</span> The victim's family.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.11" data-order="|10|52|11|" data-ref-path="10|52|11" class="h__chapter">Chapter 11 Universal Infection Control Precautions</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: February 14, 1994 (21:3 Md. R. 194)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.11.02#B" title="">Regulation .02B</a> amended effective October 27, 2003 (30:21 Md. R. 1529)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.11.03#C" title="">Regulation .03C</a> amended effective October 27, 2003 (30:21 Md. R. 1529)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.11.04#B" title="">Regulation .04B</a> amended effective October 27, 2003 (30:21 Md. R. 1529)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§18-102, 19-319(h), 19-3A-02(9) and (10), 19-705.3; Health Occupations Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=1-207" title="">1-207</a>, <a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=4-313" title="">4-313</a>(d),<br/>4-315, 6-205, 6-312, 6-505, 7-205, 7-316, 8-205, 8-316, 8-506, 14-205, 14-404, 14-415, 14-506, 15-205, 15-314, 16-205, 16-312, and 16-404; Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.11.01" data-order="|10|52|11|.01|" data-ref-path="10|52|11|.01" class="h__section">.01 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A">A.</span> These regulations apply to any of the following individuals when the individual is involved in patient care activities:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(1)">(1)</span> Acupuncturist;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(2)">(2)</span> Dental hygienist;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(3)">(3)</span> Dentist;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(4)">(4)</span> Electrologist;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(5)">(5)</span> Employee of a health care facility;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(6)">(6)</span> Employee of a health care professional;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(7)">(7)</span> Mortician;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(8)">(8)</span> Nurse;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(9)">(9)</span> Physician;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(10)">(10)</span> Physician assistant; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#A(11)">(11)</span> Podiatrist.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.01#B">B.</span> These regulations apply to any health care facility or private professional office where a health care worker is involved in patient care activities.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.11.02" data-order="|10|52|11|.02|" data-ref-path="10|52|11|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(1)">(1)</span> "Assisted living facility" has the meaning for assisted living program stated in Health-General Article, §19-1801, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(2)">(2)</span> "Day care center for adults" has the meaning stated in Health-General Article, §14-301, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(3)">(3)</span> "Freestanding birthing center" has the meaning stated in Health-General Article, §19-3B-01, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(4)">(4)</span> "Freestanding medical facility" has the meaning stated in Health-General Article, §19-3A-01, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)">(5)</span> Health Care Facility.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)">(a)</span> "Health care facility" means a location where health care is provided, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)(i)">(i)</span> Assisted living facility;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)(ii)">(ii)</span> Day care center for adults;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)(iii)">(iii)</span> Freestanding birthing center;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)(iv)">(iv)</span> Freestanding medical facility;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)(v)">(v)</span> Health maintenance organization;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)(vi)">(vi)</span> Hospital;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)(vii)">(vii)</span> Managed care organization;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)(viii)">(viii)</span> Nursing home; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(a)(ix)">(ix)</span> Related institution.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(5)(b)">(b)</span> "Health care facility" does not include a private professional office.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(6)">(6)</span> "Health care professional" means an individual who is licensed or certified under one or more of the following titles of <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Annotated Code of Maryland</a>:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(6)(a)">(a)</span> Title 4 Dentistry;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(6)(b)">(b)</span> Title 6 Electrologists;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(6)(c)">(c)</span> Title 7 Morticians;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(6)(d)">(d)</span> Title 8 Nurses;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(6)(e)">(e)</span> Title 14 Physicians;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(6)(f)">(f)</span> Title 15 Physician Assistants; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(6)(g)">(g)</span> Title 16 Podiatrists.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(7)">(7)</span> "Health care worker" means an individual who is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(7)(a)">(a)</span> A health care professional;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(7)(b)">(b)</span> An employee of a health care professional; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(7)(c)">(c)</span> An employee of a health care facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(8)">(8)</span> "Health maintenance organization" has the meaning stated in Health-General Article, §19-701, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(9)">(9)</span> "Hospital" has the meaning stated in Health-General Article, §19-301, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(10)">(10)</span> "Managed care organization" has the meaning stated in Health-General Article, §15-101, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(11)">(11)</span> "Nursing home" means either:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(11)(a)">(a)</span> A comprehensive care facility, as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.07.02.01#B(6)" title="">COMAR 10.07.02.01B(6)</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(11)(b)">(b)</span> An extended care facility, as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.07.02.01#B(12)" title="">COMAR 10.07.02.01B(12)</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(12)">(12)</span> "Patient care activity" means an action performed by a health care worker for a patient which could result in one or more of the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(12)(a)">(a)</span> Blood or body fluids of the patient touching non-intact skin or mucous membrane of the health care worker;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(12)(b)">(b)</span> Blood or body fluids of the health care worker touching nonintact skin or mucous membrane of the patient;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(12)(c)">(c)</span> Percutaneous contact of the health care worker with the blood or body fluids of the patient; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(12)(d)">(d)</span> Percutaneous contact of the patient with the blood or body fluids of the health care worker.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(13)">(13)</span> "Private professional office" means a location which is not a part of a health care facility where a health care professional provides services to the public on a regular basis.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(14)">(14)</span> "Related institution" has the meaning stated in Health-General Article, §19-301, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.02#B(15)">(15)</span> "Universal precautions" has the meaning stated in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.06.01.02#B(10)" title="">COMAR 10.06.01.02B(10)</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.11.03" data-order="|10|52|11|.03|" data-ref-path="10|52|11|.03" class="h__section">.03 Compliance Requirements for an Individual.</h3>
                <p>An individual who is performing patient care activities shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.03#A">A.</span> Comply with the principles of universal precautions;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.03#B">B.</span> If necessary, make an emergency exception to the use of universal precautions in a situation when failure to provide immediate care could result in serious harm to or death of a patient; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.03#C">C.</span> Comply with current professional standards of patient care with regard to disinfection and sterilization of reusable devices used in patient care procedures, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.03#C(1)">(1)</span> Prohibiting the reuse of single use needles; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.03#C(2)">(2)</span> Properly disposing of needles and other sharps devices.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.11.04" data-order="|10|52|11|.04|" data-ref-path="10|52|11|.04" class="h__section">.04 Compliance Requirements for a Health Care Facility.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.04#A">A.</span> A health care facility shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.04#A(1)">(1)</span> Adopt, implement, and enforce a policy that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.04#A(1)(a)">(a)</span> Requires the use of universal precautions by medical staff and employees engaged in patient care activities,</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.04#A(1)(b)">(b)</span> Permits an individual to make an emergency exception to the use of universal precautions, at the individual's discretion, in a situation where failure to provide immediate care could result in serious harm to or death of a patient, and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.04#A(1)(c)">(c)</span> Requires compliance with current professional standards of patient care with regard to disinfection and sterilization of reusable devices used in patient care procedures; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.04#A(2)">(2)</span> Display the version of the notice "We Take Precautions for You" specified in Table A, shown in <a class="internal-link " href="/us/md/exec/comar/10.52.11.04#B" title="">§B of this regulation</a>, at the entrance to the health care facility.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.04#B">B.</span> Table A.</p>
                <div class="table_wrap">
                  <table class="layout-table">
                    <tbody>
                      <tr>
                        <td>Type of Facility</td>
                        <td>Version</td>
                      </tr>
                      <tr>
                        <td>Assisted living facility</td>
                        <td>MDH 4469 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Day care center for adults</td>
                        <td>MDH 4469 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Clinic</td>
                        <td>MDH 4475 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Freestanding birthing center</td>
                        <td>MDH 4469 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Freestanding medical facility</td>
                        <td>MDH 4469 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Health maintenance organization</td>
                        <td>MDH 4469 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Hospital</td>
                        <td>MDH 4468 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Managed care organization</td>
                        <td>MDH 4469 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Nursing home</td>
                        <td>MDH 4469 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Related institution</td>
                        <td>MDH 4469 (1-93)</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.11.05" data-order="|10|52|11|.05|" data-ref-path="10|52|11|.05" class="h__section">.05 Compliance Requirements for Health Care Professional with Private Professional Office.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.05#A">A.</span> A health care professional who practices in a private professional office shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.05#A(1)">(1)</span> Ensure that an individual who performs patient care services in the professional's office:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.05#A(1)(a)">(a)</span> Complies with the principles of universal precautions,</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.05#A(1)(b)">(b)</span> Is permitted to make an emergency exception to the use of universal precautions, at the individual's discretion, in a situation where failure to provide immediate care could result in serious harm to or death of a patient, and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.11.05#A(1)(c)">(c)</span> Complies with current professional standards of patient care with regard to disinfection and sterilization of reusable devices used in patient care procedures; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.11.05#A(2)">(2)</span> Except as provided in <a class="internal-link " href="/us/md/exec/comar/10.52.11.05#C" title="">§C of this regulation</a>, display the version of the notice "We Take Precautions for You" specified in Table B shown in <a class="internal-link " href="/us/md/exec/comar/10.52.11.05#B" title="">§B of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.05#B">B.</span> Table B.</p>
                <div class="table_wrap">
                  <table class="layout-table">
                    <tbody>
                      <tr>
                        <td>Type of Health Care Professional</td>
                        <td>Version</td>
                      </tr>
                      <tr>
                        <td>Acupuncturist</td>
                        <td>MDH 4472 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Dentist</td>
                        <td>MDH 4471 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Electrologist</td>
                        <td>MDH 4474 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Nurse</td>
                        <td>MDH 4470 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Physician</td>
                        <td>MDH 4472 (1-93)</td>
                      </tr>
                      <tr>
                        <td>Podiatrist</td>
                        <td>MDH 4473 (1-93)</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.11.05#C">C.</span> A health care professional not listed in Table B is not required to post the notice "We Take Precautions for You".</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.12" data-order="|10|52|12|" data-ref-path="10|52|12" class="h__chapter">Chapter 12 Newborn Screening</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: December 24, 1975 (2:29 Md. R. 1738)</p>
                  <p>Chapter revised and recodified from <a class="internal-link no-wrap" href="/us/md/exec/comar/10.39.01" title="Chapter 01 Certification of Nursing Assistants">COMAR 10.39.01</a>, Testing for Hereditary Metabolic Disorders in the Newborn Child, to <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12" title="Chapter 12 Newborn Screening">COMAR 10.52.12</a>, Screening for Treatable Disorders in the Newborn Child, effective November 20, 1994 (21:23 Md. R. 1934)</p>
                  <p>——————</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12.01" title=".01 Purpose.">.01</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12.12" title=".12 Follow-Up Procedures.">.12</a>, Screening for Treatable Disorders in the Newborn Child, repealed and new Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12.01" title=".01 Purpose.">.01</a>—.15, Newborn Screening, adopted as an emergency provision effective January 1, 2009 (36:2 Md. R. 97); adopted permanently effective March 23, 2009 (36:6 Md. R. 490)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12.03#B" title="">Regulation .03B</a> amended effective March 14, 2016 (43:5 Md. R. 385)</p>
                  <p>Regulation .07E amended effective March 14, 2016 (43:5 Md. R. 385)</p>
                  <p>Regulation .08B amended effective March 14, 2016 (43:5 Md. R. 385)</p>
                  <p>——————</p>
                  <p>Chapter revised effective April 24, 2017 (44:8 Md. R. 404)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.12.05#B" title="">Regulation .05B</a> amended effective August 23, 2021 (48:17 Md. R. 669); April 14, 2025 (52:7 Md. R. 321)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§13-109, 13-111, and 13-601—13-605, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.12.01" data-order="|10|52|12|.01|" data-ref-path="10|52|12|.01" class="h__section">.01 Purpose.</h3>
                <p>This chapter and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13" title="Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants">COMAR 10.10.13</a> establish a coordinated Statewide system for:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.01#A">A.</span> Laboratory screening of newborn infants in the State for certain hereditary and congenital disorders associated with severe problems of health or development; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.01#B">B.</span> Follow-up services to those infants with abnormal screening results.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.02" data-order="|10|52|12|.02|" data-ref-path="10|52|12|.02" class="h__section">.02 Scope.</h3>
                <p>This chapter identifies standards and requirements for the Department, birthing facilities, and persons participating in one or more aspects of Maryland's Newborn Screening Program for hereditary and congenital disorders.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.03" data-order="|10|52|12|.03|" data-ref-path="10|52|12|.03" class="h__section">.03 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(1)">(1)</span> Birthing Facility.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(1)(a)">(a)</span> "Birthing facility" means a facility that provides the antepartum, intrapartum, and postpartum management and care of women and their newborn infants.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(1)(b)">(b)</span> "Birthing facility" includes a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(1)(b)(i)">(i)</span> Birthing service that is licensed or accredited as a unit of a hospital; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(1)(b)(ii)">(ii)</span> Freestanding birthing center as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.05.02.01#B" title="">COMAR 10.05.02.01B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(2)">(2)</span> Blood-Spot Specimen.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(2)(a)">(a)</span> “Blood-spot specimen” means a whole-blood specimen collected from a newborn infant’s heel and applied to the designated area on a blood-spot specimen collection test requisition card for the purpose of performing screening tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(2)(b)">(b)</span> “Blood-spot specimen” includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(2)(b)(i)">(i)</span> The first screening blood-spot specimen collected from a newborn infant, usually in the birthing facility or other place where the newborn infant was born, within 48 hours after the newborn infant’s birth;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(2)(b)(ii)">(ii)</span> The second screening blood-spot specimen collected from a newborn infant, usually collected when the newborn infant is between 10 and 14 days of age; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(2)(b)(iii)">(iii)</span> A blood-spot specimen collected subsequent to a specimen specified in §B(2)(b)(i) and (ii) of this regulation as required to meet the medical needs and condition of the newborn infant and any additional specific screening blood-spot specimen collection and screening test requirements of this chapter and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13" title="Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants">COMAR 10.10.13</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(3)">(3)</span> Congenital Disorder.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(3)(a)">(a)</span> "Congenital disorder" means a significant structural or functional abnormality of the body that is present at birth.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(3)(b)">(b)</span> "Congenital disorder" does not include a condition that results from:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(3)(b)(i)">(i)</span> An intrauterine infection; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(3)(b)(ii)">(ii)</span> A birth injury.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(4)">(4)</span> "Council" means the State Advisory Council on Hereditary and Congenital Disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(5)">(5)</span> “Courier” means an entity employed by a person to convey a blood-spot specimen from the site of blood-spot specimen collection to the laboratory where the blood-spot specimen will be tested.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(6)">(6)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(7)">(7)</span> "Diagnostic test" means a test that is used to establish or confirm the presence of a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(7)(a)">(a)</span> Specific disease; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(7)(b)">(b)</span> Hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(8)">(8)</span> “First screening” means a screening performed on the first blood-spot specimen collected from a newborn infant after birth.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(9)">(9)</span> "First-tier test" means a blood test performed on a newborn infant's blood that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(9)(a)">(a)</span> Indicates the probable presence or absence of a hereditary or congenital disorder; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(9)(b)">(b)</span> Identifies a newborn infant who is at increased risk for a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(10)">(10)</span> “Follow-Up Unit” means the follow-up component and staff of the Department’s Newborn Screening Program, which carries out the duties set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.12.12" title=".12 Follow-Up Procedures.">Regulation .12 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(11)">(11)</span> Hereditary Disorder.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(11)(a)">(a)</span> "Hereditary disorder" means a disorder that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(11)(a)(i)">(i)</span> Is transmissible through the genetic material deoxyribonucleic acid (DNA); or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(11)(a)(ii)">(ii)</span> Arises through the improper processing of information in the genetic material.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(11)(b)">(b)</span> "Hereditary disorder" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(11)(b)(i)">(i)</span> Hemoglobin disorders;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(11)(b)(ii)">(ii)</span> Metabolic disorders; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(11)(b)(iii)">(iii)</span> Endocrine disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(12)">(12)</span> “Home birth” means the birth of an infant which occurs intentionally outside of a birthing facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(13)">(13)</span> “Home birth attendant” means a physician who is licensed to practice under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 14, Annotated Code of Maryland</a>, a nurse midwife who is licensed and certified to practice under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 8, Annotated Code of Maryland</a>, or a direct-entry midwife who is licensed under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gho/gho.pdf" title="">Health Occupations Article, Title 8, Subtitle 6C, Annotated Code of Maryland</a>, who is caring for the mother and infant at delivery during a home birth as defined in <a class="internal-link " href="/us/md/exec/comar/10.52.12.03#B(12)" title="">§B(12) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(14)">(14)</span> "Metabolic disorder" means a disorder caused by a genetic alteration that results in a defect in the function of a specific enzyme, hormone, or protein, which can be detected by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(14)(a)">(a)</span> Direct analysis of the enzyme, hormone, or protein; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(14)(b)">(b)</span> Testing for a substance whose metabolism is altered as a result of the defect.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(15)">(15)</span> "Milk feeding" means feedings received for 24 hours by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(15)(a)">(a)</span> A healthy newborn infant on a diet of milk; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(15)(b)">(b)</span> An ill or premature newborn infant on parenteral feedings providing a minimum of 1 gram of protein per kilogram of body weight per day and 75 kilocalories per kilogram of body weight per day.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)">(16)</span> "Newborn" or "newborn infant" means an infant:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)(a)">(a)</span> Born in Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)(b)">(b)</span> Born on federal property within Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)(c)">(c)</span> Born outside of Maryland to parents whose residence is in Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)(d)">(d)</span> From whom a blood-spot specimen was collected and submitted to the State’s public health laboratory for newborn screening by a birthing facility or other health care provider located in Maryland, regardless of the infant’s place of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)(e)">(e)</span> Who has a screening test requested by the Follow-Up Unit:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)(e)(i)">(i)</span> For first-tier screening follow-up;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)(e)(ii)">(ii)</span> For confirmation of a previous screening test result; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)(e)(iii)">(iii)</span> To assist with the infant's diagnosis, therapy, or follow-up care; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(16)(f)">(f)</span> Who is in Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(17)">(17)</span> Newborn Screening or Screening.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(17)(a)">(a)</span> "Newborn screening" or "screening" means one or more first-tier tests.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(17)(b)">(b)</span> "Newborn screening" or "screening" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(17)(b)(i)">(i)</span> First-tier testing on a first, second, or subsequent blood-spot specimen; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(17)(b)(ii)">(ii)</span> Supplemental first-tier testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)">(18)</span> Newborn Screening Program.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(a)">(a)</span> "Newborn Screening Program" means the Department's screening program for hereditary and congenital disorders, which performs operations and activities necessary to ensure that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(a)(i)">(i)</span> Newborn infants are given the opportunity to be tested;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(a)(ii)">(ii)</span> At risk newborn infants who are tested are identified and located;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(a)(iii)">(iii)</span> Newborn infants are given access to necessary follow-up testing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(a)(iv)">(iv)</span> Diagnostic tests are available and the diagnosis is made or ruled out; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(a)(v)">(v)</span> Newborn infants diagnosed with a hereditary or congenital disorder are given access to treatment.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(b)">(b)</span> "Newborn Screening Program" includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(b)(i)">(i)</span> The Department's public health laboratory as the sole screening laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(b)(ii)">(ii)</span> Another state's public health laboratory or a commercial laboratory that may serve the State as a screening laboratory during an emergency under a formal Departmental mutual aid agreement;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(b)(iii)">(iii)</span> Supplemental and second-tier testing performed by a state public health laboratory or by a licensed commercial or research laboratory;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(b)(iv)">(iv)</span> The Follow-Up Unit; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(18)(b)(v)">(v)</span> The State Advisory Council on Hereditary and Congenital Disorders.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(19)">(19)</span> “Second screening” means a test performed on a routine second blood-spot specimen collected when the newborn infant is between 10 and 14 days old even though the test results from the newborn’s first blood-spot specimen were normal.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(20)">(20)</span> Second-Tier Test.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(20)(a)">(a)</span> “Second-tier test” means a test performed on a newborn screening blood-spot specimen when a first-tier test provides an abnormal screening test result or a borderline abnormal screening test result.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(20)(b)">(b)</span> "Second-tier test" includes a test that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(20)(b)(i)">(i)</span> Establishes or confirms a newborn infant's risk for a hereditary or congenital disorder;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(20)(b)(ii)">(ii)</span> Separates a newborn infant into a lower or higher risk category for a hereditary or congenital disorder; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(20)(b)(iii)">(iii)</span> Is diagnostic because it confirms the presence of a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(21)">(21)</span> “Supplemental test” means a test performed on a blood-spot specimen collected from a newborn infant that is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(21)(a)">(a)</span> Used to detect a hereditary or congenital disorder not specified in <a class="internal-link " href="/us/md/exec/comar/10.52.12.05" title=".05 Selection of Disorders for Screening.">Regulation .05 of this chapter</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(21)(b)">(b)</span> Not required to be performed by the Department's public health laboratory under this chapter or <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13" title="Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants">COMAR 10.10.13</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.03#B(22)">(22)</span> “Unsatisfactory blood-spot specimen” means a blood-spot specimen that may produce an inaccurate or unreliable test result because the blood-spot specimen exhibits one of the problems of collection as specified in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.21#B" title="">COMAR 10.10.13.21B</a> and C.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.04" data-order="|10|52|12|.04|" data-ref-path="10|52|12|.04" class="h__section">.04 Responsibilities of the Department.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.04#A">A.</span> Program Maintenance. The Department shall operate a Newborn Screening Program to identify congenital and hereditary disorders and provide follow-up services to newborn infants.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.04#B">B.</span> Laboratory Oversight. The Department shall ensure that a laboratory holding a permit to offer or perform first-tier, supplemental, or second-tier tests to identify congenital and hereditary disorders in newborn infants is subjected to regulatory oversight that includes surveys and proficiency testing as set forth in:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.04#B(1)">(1)</span> <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.02" title="Chapter 02 Medical Laboratories — General">COMAR 10.10.02</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.04#B(2)">(2)</span> <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05" title="Chapter 05 Medical Laboratories — Proficiency Testing">COMAR 10.10.05</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.04#C">C.</span> Notification. The Department shall notify the parents and guardians of newborn infants that laboratories other than the Department’s public health laboratory may perform post screening confirmatory or diagnostic tests on newborn infants for hereditary and congenital disorders.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.05" data-order="|10|52|12|.05|" data-ref-path="10|52|12|.05" class="h__section">.05 Selection of Disorders for Screening.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#A">A.</span> The Department, with the advice of the Council, shall select the disorders for which screening is required by the Newborn Screening Program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B">B.</span> The selected disorders are:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(1)">(1)</span> Biotinidase deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(2)">(2)</span> Congenital adrenal hyperplasia (CAH);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(3)">(3)</span> Hypothyroidism;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(4)">(4)</span> Galactosemia, galactose-1-phosphate uridyl transferase deficiency (GALT);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(5)">(5)</span> Epimerase Galactosemia, uridine diphosphate-galactose-4-epimerase deficiency (GALE);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(6)">(6)</span> Galactokinase Galactosemia, galactokinase deficiency (GALK1);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(7)">(7)</span> Sickle cell disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(8)">(8)</span> Sickle cell disease: S beta-thalessemia;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(9)">(9)</span> Sickle C disease: SC disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(10)">(10)</span> Other hemoglobin variants;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(11)">(11)</span> Phenylketonuria (PKU);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(12)">(12)</span> Hyperphenylalaninemia (Hyper-PHE);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(13)">(13)</span> Biopterin cofactor biosynthesis defects (BIOPT-BS);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(14)">(14)</span> Biopterin cofactor regeneration defects (BIOPT-REG);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(15)">(15)</span> Tyrosinemia, type I;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(16)">(16)</span> Tyrosinemia, type II;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(17)">(17)</span> Tyrosinemia, type III;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(18)">(18)</span> Homocystinuria;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(19)">(19)</span> Hypermethioninemia;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(20)">(20)</span> Branched chain ketoaciduria (BCK), also called maple syrup urine disease (MSUD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(21)">(21)</span> Citrullinemia, type I;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(22)">(22)</span> Citrullinemia, type II;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(23)">(23)</span> Arginosuccinic aciduria;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(24)">(24)</span> Argininemia;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(25)">(25)</span> Methylmalonic acidemia, mutase deficiency (MMA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(26)">(26)</span> Methylmalonic acidemia, adenosylcobalamin synthesis defects A and B (Cbl A, B);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(27)">(27)</span> Methylmalonic acidemia, adenosylcobalamin synthesis defects C and D (Cbl C, D);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(28)">(28)</span> Propionic acidemia (PA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(29)">(29)</span> Isovaleric acidemia (IVA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(30)">(30)</span> Glutaric aciduria type I (GA I);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(31)">(31)</span> 3-Hydroxy-3-methylglutaryl-CoA (HMG) lysase deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(32)">(32)</span> Isobutryl-CoA dehydrogenase (IBCD) deficiency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(33)">(33)</span> 2-Methylbutyryl-CoA dehydrogenase deficiency (2MBG);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(34)">(34)</span> 3-Methlycrotonyl-CoA carboxylase deficiency (3MCC);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(35)">(35)</span> 3-Methlyglutaconyl-CoA hydratase deficiency (3MGA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(36)">(36)</span> 2-Methyl-3-hydroxybutyrl-CoA dehydrogenase deficiency (2M3HBA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(37)">(37)</span> Mitochondrial acetoacetyl-CoA thiolase (3-ketothiolase) deficiency (BKT);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(38)">(38)</span> Multiple carboxylase deficiency (MCD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(39)">(39)</span> Malonic acidemia (MAL);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(40)">(40)</span> Medium chain acyl-CoA dehydrogenase deficiency (MCAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(41)">(41)</span> Medium chain ketoacyl-CoA thiolase deficiency (MCKAT);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(42)">(42)</span> Short chain acyl-CoA dehydrogenase deficiency (SCAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(43)">(43)</span> Short chain 3-hydroxy acyl Co-A dehydrogenase deficiency (SCHAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(44)">(44)</span> Very long chain acyl-CoA dehydrogenase deficiency (VLCAD)</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(45)">(45)</span> 3-hydroxy long chain acyl-CoA dehydrogenase deficiency (LCHAD);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(46)">(46)</span> Multiple acyl-CoA dehydrogenase (MAD) or glutaric acidemia type II deficiency (GA II);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(47)">(47)</span> Carnitine/acylcarnitine translocase deficiency (translocase deficiency);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(48)">(48)</span> Carnitine palmitoyl transferase type I deficiency (CPT I);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(49)">(49)</span> Carnitine palmitoyl transferase type II deficiency (CPT II);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(50)">(50)</span> Carnitine uptake disorder;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(51)">(51)</span> Trifunctional protein deficiency (TFP);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(52)">(52)</span> 2,4-dienoyl-CoA reductase deficiency (DE RED);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(53)">(53)</span> Cystic fibrosis;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(54)">(54)</span> Severe combined immunodeficiency (SCID);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(55)">(55)</span> Pompe disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(56)">(56)</span> Fabry disease;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(57)">(57)</span> Spinal muscular atrophy (SMA);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(58)">(58)</span> Mucopolysaccharidosis type I (MPS I);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(59)">(59)</span> Mucopolysaccharidosis Type II (MPS II);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(60)">(60)</span> X-linked Adrenoleukodystrophy (X-ALD); and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#B(61)">(61)</span> Guanidinoacetate Methyltransferase Deficiency (GAMT).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.05#C">C.</span> Supplemental Tests. The State’s Newborn Screening Program may not request or perform a supplemental test until the public health laboratory has confirmed there is sufficient blood-spot specimen to test for the required panel of disorders set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.12.05#B" title="">§B of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.06" data-order="|10|52|12|.06|" data-ref-path="10|52|12|.06" class="h__section">.06 Pre-Test Information.</h3>
                <p>Before a blood-spot specimen is sent for newborn screening, a health care provider or the individual’s designated representative shall provide to the newborn infant’s parent or guardian an explanation of newborn screening that includes:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.06#A">A.</span> Reasons for newborn screening, including the;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.06#A(1)">(1)</span> Purpose of the testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.06#A(2)">(2)</span> Nature and consequences of being affected by a hereditary or congenital disorder or being a carrier of a hereditary or congenital disorder; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.06#B">B.</span> A parent or guardian's right to object to having the testing performed, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.06#B(1)">(1)</span> Stating that newborn screening is wholly voluntary;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.06#B(2)">(2)</span> Explaining any risk involved in having newborn screening performed; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.06#B(3)">(3)</span> Providing a reasonable opportunity to object to screening.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.07" data-order="|10|52|12|.07|" data-ref-path="10|52|12|.07" class="h__section">.07 Initial Screening.</h3>
                <p>The individual in charge of a birthing facility or the individual’s designated representative, or the home birth attendant shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#A">A.</span> If the parent or guardian of the newborn infant does not object to newborn screening:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#A(1)">(1)</span> Collect a blood-spot specimen:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#A(1)(a)">(a)</span> As set forth in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#A(1)(a)(i)">(i)</span> Sections C and D of this regulation; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#A(1)(a)(ii)">(ii)</span> <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.13" title=".13 Screening Test Blood-Spot Specimens — Collection and Test Requisition.">COMAR 10.10.13.13</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#A(1)(b)">(b)</span> Pursuant to the procedures established in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.14#A" title="">COMAR 10.10.13.14A</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#A(2)">(2)</span> Submit the collected blood-spot specimen to the Department’s public health laboratory;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#B">B.</span> When a parent or guardian objects to newborn screening:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#B(1)">(1)</span> Have the parent or guardian sign a form that states the parent or guardian objects to newborn screening; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#B(2)">(2)</span> Inform the Follow-Up Unit by telephone, fax, or email of the objection within 12 hours after the objection;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#C">C.</span> For full-term healthy newborn infants:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#C(1)">(1)</span> Collect a blood-spot specimen to test for the disorders set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.12.05" title=".05 Selection of Disorders for Screening.">Regulation .05 of this chapter</a> not sooner than 24 hours after the onset of milk feeding, regardless of whether the newborn is breast-fed or formula-fed; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#C(2)">(2)</span> If the newborn infant is discharged before 24 hours after the onset of milk feeding, collect the blood-spot specimen as late as practical before the newborn infant is discharged from the birthing facility; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#D">D.</span> For a newborn infant born prematurely or expected to be ill for longer than 14 days, if the newborn infant’s medical condition permits, collect:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#D(1)">(1)</span> A blood-spot specimen for the newborn screening test upon admission, before the administration of blood products or antibiotics;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#D(2)">(2)</span> A subsequent blood-spot specimen 48 to 72 hours after birth, regardless of milk feeding status;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#D(3)">(3)</span> A subsequent blood-spot specimen by 10 days of age when milk feeding is established or the infant has been receiving additional protein through intravenous fluids; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.07#D(4)">(4)</span> An additional subsequent blood-spot specimen at one month of age or at discharge, whichever comes first.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.08" data-order="|10|52|12|.08|" data-ref-path="10|52|12|.08" class="h__section">.08 Second Screening.</h3>
                <p>A health care provider shall have a blood-spot specimen collected for a second screening for the disorders set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.12.05" title=".05 Selection of Disorders for Screening.">Regulation .05 of this chapter</a> when the newborn is between 10 and 14 days old.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.09" data-order="|10|52|12|.09|" data-ref-path="10|52|12|.09" class="h__section">.09 Transport of Blood-Spot Specimens to a Licensed Laboratory.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.09#A">A.</span> A birthing facility representative, physician, or other health care provider or, in the case when a birth occurs outside a birthing facility, the individual required to prepare and file the certificate of birth, shall send newborn screening blood-spot specimens only to the Department’s public health laboratory for the performance of newborn screening, as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.14#B" title="">COMAR 10.10.13.14B</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.09#B">B.</span> The individual responsible for collecting and submitting a blood-spot specimen for a newborn screening test shall ensure that blood-spot specimens are forwarded by courier to the Department’s public health laboratory within 24 hours after collection.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.10" data-order="|10|52|12|.10|" data-ref-path="10|52|12|.10" class="h__section">.10 Results.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#A">A.</span> Normal Screening Results.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#A(1)">(1)</span> The Department’s public health laboratory shall report normal newborn screening test results to the submitter of the blood-spot specimen within 3 business days after receipt of the blood-spot specimen.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#A(2)">(2)</span> A birthing facility representative, health care provider, or the individual who is responsible for filing the certificate of birth if the birth occurs outside a birthing facility, or other submitter of the blood-spot specimen shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#A(2)(a)">(a)</span> Enter the results in the newborn infant's medical record; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#A(2)(b)">(b)</span> Make the results available to the parent, guardian, or primary care providers upon request.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#B">B.</span> Abnormal Screening Results.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#B(1)">(1)</span> The Department’s public health laboratory shall immediately report abnormal newborn screening test results to the Follow-Up Unit.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#B(2)">(2)</span> The Department’s public health laboratory shall report to the Follow-Up Unit all known demographic and clinical data on the newborn infant in an electronic format compatible with the Department’s information system databases operated by the Department’s public health laboratory, as set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13.25" title=".25 Reporting System and Communication Software.">COMAR 10.10.13.25</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#B(3)">(3)</span> The Follow-Up Unit shall enter results in the Department’s database and initiate follow-up procedures as specified in <a class="internal-link " href="/us/md/exec/comar/10.52.12.12" title=".12 Follow-Up Procedures.">Regulation .12 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#B(4)">(4)</span> The submitter of the blood-spot specimen shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#B(4)(a)">(a)</span> Enter the results in the newborn infant's medical record; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.10#B(4)(b)">(b)</span> Make the abnormal results available immediately to the newborn's parent, guardian, or primary care providers.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.11" data-order="|10|52|12|.11|" data-ref-path="10|52|12|.11" class="h__section">.11 Referral Procedures.</h3>
                <p>The individual in charge of a birthing facility or the individual’s designated representative, or the home birth attendant shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.11#A">A.</span> Develop collection and transport procedures to ensure against collecting and submitting unsatisfactory blood-spot specimens for each of the categories of newborn infant listed in <a class="internal-link " href="/us/md/exec/comar/10.52.12.11#B" title="">§B of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.11#B">B.</span> Collect or otherwise have collected:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.11#B(1)">(1)</span> An additional blood-spot specimen before the newborn is 7 days old for newborn infants discharged before 24 hours of milk feeding in addition to the blood-spot specimen collected before discharge, as set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.12.07#C(2)" title="">Regulation .07C(2) of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.11#B(2)">(2)</span> The blood-spot specimen before the newborn is 7 days old if a newborn infant is discharged from a birthing facility before a newborn screening blood-spot specimen is collected.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.11#B(3)">(3)</span> An additional blood-spot specimen within 7 days after notification if the laboratory reports to a birthing facility or a home birth attendant that the initial blood-spot specimen was unsatisfactory.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.11#B(4)">(4)</span> A blood-spot specimen to be tested for hemoglobins, biotinidase, and galastose -1 phosphate uridyl transferase (GALT) only, four months after the last transfusion if the initial blood-spot specimen was not collected until after the infant was transfused.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.12" data-order="|10|52|12|.12|" data-ref-path="10|52|12|.12" class="h__section">.12 Follow-Up Procedures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A">A.</span> Department's Responsibilities.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(1)">(1)</span> The Follow-Up Unit shall investigate each abnormal result indicative of increased risk for a hereditary or congenital disorder by contacting the infant’s health care provider, or other appropriate individual to notify the parent or guardian, or if the health care provider cannot be contacted, by contacting the infant’s parent or guardian directly regarding:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(1)(a)">(a)</span> Results of first-tier, supplemental, and second-tier tests;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(1)(b)">(b)</span> The importance of identifying and locating a newborn infant with test results indicative of increased risk for an hereditary or congenital disorder;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(1)(c)">(c)</span> The urgent need for follow-up; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(1)(d)">(d)</span> The need to share newborn screening information between hospitals, healthcare providers, treatment centers, and laboratory personnel.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(2)">(2)</span> If the parent or guardian fails to respond to the birthing facility, health care provider, or other responsible individual acting as set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.12.12#B(1)" title="">§B(1) of this regulation</a>, the individual in charge of the birthing facility or the individual’s designated representative, health care provider, or other responsible individual shall notify the Follow-Up Unit, which shall then try to notify the parent or guardian of the need for follow-up by using at least one of the following means, in the indicated order of priority:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(2)(a)">(a)</span> Telephone;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(2)(b)">(b)</span> Certified mail, if medically appropriate;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(2)(c)">(c)</span> Public health nurse visit; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(2)(d)">(d)</span> Law enforcement contact.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(3)">(3)</span> The Follow-Up Unit shall provide recommendations to the responsible birthing facility, health care provider, and the parent or guardian, as appropriate, regarding the appropriate follow-up and diagnostic evaluation of the newborn infant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(4)">(4)</span> The Follow-Up Unit shall recommend:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(4)(a)">(a)</span> Sources of diagnostic evaluation, specialty care, and treatment; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(4)(b)">(b)</span> That no treatment be administered to the newborn infant until the results of the follow-up evaluation have established that the infant has a hereditary or congenital disorder.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(5)">(5)</span> The Follow-Up Unit shall inform health care personnel and parents or guardians of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(5)(a)">(a)</span> The nature, cost, benefits, and risks of any therapy; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#A(5)(b)">(b)</span> The availability of any programs to assist individuals affected by a hereditary or congenital disorder.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#B">B.</span> Responsibilities of the Birthing Facility or Health Care Provider. The individual in charge of the birthing facility or individual’s designated representative or health care provider shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#B(1)">(1)</span> Evaluate the infant for signs, symptoms, and biochemical evidence of a hereditary or congenital disorder;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#B(2)">(2)</span> Refer the newborn infant for further evaluation:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#B(2)(a)">(a)</span> To the appropriate specialists; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#B(2)(b)">(b)</span> For the appropriate diagnostic tests;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#B(3)">(3)</span> Collect and submit any required blood-spot specimens for repeat screening or diagnostic testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.12#B(4)">(4)</span> Report the results of diagnostic testing to the Follow-Up Unit.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.12.13" data-order="|10|52|12|.13|" data-ref-path="10|52|12|.13" class="h__section">.13 Records.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#A">A.</span> The screening of newborn infants pursuant to this chapter is a population based public health surveillance program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#B">B.</span> On request, a laboratory or health care provider shall make available to the Follow-Up Unit medical records, records of laboratory tests, and any other medical information the Follow-Up Unit considers necessary to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#B(1)">(1)</span> Screen a newborn infant for hereditary and congenital disorders set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.12.05" title=".05 Selection of Disorders for Screening.">Regulation .05 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#B(2)">(2)</span> Carry out the State's Newborn Screening Program, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#B(2)(a)">(a)</span> Contacting the families and primary health care providers of newborn infants with newborn screening test results indicating a high risk of having a hereditary or congenital disorder;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#B(2)(b)">(b)</span> Providing recommendations regarding the appropriate follow-up and diagnostic evaluation of the newborn infant;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#B(2)(c)">(c)</span> Determining what follow-up evaluations and diagnostic tests were performed and on what date the evaluations and tests were performed;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#B(2)(d)">(d)</span> Determining if and on what date a diagnosis of a specific hereditary or congenital disorder in a newborn infant was made; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#B(2)(e)">(e)</span> Determining if and on what date treatment and follow-up care have been initiated; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#B(3)">(3)</span> Ensure compliance with the pertinent regulations set forth in this chapter and in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.13" title="Chapter 13 Medical Laboratories — Testing for Hereditary and Congenital Disorders in Newborn Infants">COMAR 10.10.13</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#C">C.</span> Information that the Department receives under this chapter is confidential and may only be used or disclosed:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#C(1)">(1)</span> To provide services to the newborn infant and the infant's family;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#C(2)">(2)</span> To study the relationships of the various factors determining the frequency and distribution of the disorders set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.12.05" title=".05 Selection of Disorders for Screening.">Regulation .05 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#C(3)">(3)</span> For State or federally mandated statistical reports; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.12.13#C(4)">(4)</span> To ensure that the information received by the Department is accurate and reliable.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.13" data-order="|10|52|13|" data-ref-path="10|52|13" class="h__chapter">Chapter 13 Screening for Sickle-Cell Disease, Thalassemia, and Related Conditions</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: June 16, 1978 (5:12 Md. R. 968)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.39.02" title="Chapter 02 Nursing Assistant Training Programs">COMAR 10.39.02</a>, Screening for Sickle Cell, Thalassemia, and Related Conditions, revised and recodified to <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.13" title="Chapter 13 Screening for Sickle-Cell Disease, Thalassemia, and Related Conditions">COMAR 10.52.13</a>, Screening for Sickle Cell Disease, Thalassemia, and Related Conditions, effective April 24, 1995 (22:8 Md. R. 596)</p>
                  <p>——————</p>
                  <p>Regulations .01—.10 repealed effective December 10, 2012 (39:24 Md. R. 1578)</p>
                </section>
                <h2 id="/us/md/exec/comar/10.52.14" data-order="|10|52|14|" data-ref-path="10|52|14" class="h__chapter">Chapter 14 Screening for Neural Tube Defects in the Fetus</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: December 15, 1986 (13:25 Md. R. 2660)</p>
                  <p>Chapter revised and recodified from <a class="internal-link no-wrap" href="/us/md/exec/comar/10.39.03" title="Chapter 03 Certified Medicine Aides">COMAR 10.39.03</a> to <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.14" title="Chapter 14 Screening for Neural Tube Defects in the Fetus">COMAR 10.52.14</a> effective January 2, 1995 (21:26 Md. R. 2188)</p>
                  <p>——————</p>
                  <p>Regulations .01—.06 repealed effective December 10, 2012 (39:24 Md. R. 1578)</p>
                </section>
                <h2 id="/us/md/exec/comar/10.52.15" data-order="|10|52|15|" data-ref-path="10|52|15" class="h__chapter">Chapter 15 Screening for Critical Congenital Heart Disease (CCHD) in Newborns</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.15.01" title=".01 Purpose and Scope.">.01</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.15.08" title=".08 Records.">.08</a> adopted as an emergency provision effective October 5, 2012 (39:22 Md. R. 1427); emergency status extended to June 1, 2013 (40:6 Md. R. 469); adopted permanently effective April 15, 2013 (40:7 Md. R. 612)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§13-109, 13-111, and 18-107(a), Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.15.01" data-order="|10|52|15|.01|" data-ref-path="10|52|15|.01" class="h__section">.01 Purpose and Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.01#A">A.</span> This chapter establishes Statewide screening protocols for critical congenital heart disease in newborn infants.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.01#B">B.</span> This chapter identifies standards and requirements for the Department, birthing facilities, nurse midwives, and persons participating in newborn screening for critical congenital heart disease.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.15.02" data-order="|10|52|15|.02|" data-ref-path="10|52|15|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(1)">(1)</span> “Attending clinician” means an individual who is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(1)(a)">(a)</span> A health care provider as defined in Health-General Article, §5-601, Annotated Code of Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(1)(b)">(b)</span> Responsible for the care of newborn infants, and is either:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(1)(b)(i)">(i)</span> A certified nurse practitioner licensed by the Maryland Board of Nursing; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(1)(b)(ii)">(ii)</span> A certified nurse midwife licensed by the Maryland Board of Nursing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(2)">(2)</span> “Attending physician” means an individual who is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(2)(a)">(a)</span> A health care provider as defined in Health-General Article, §5-601, Annotated Code of Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(2)(b)">(b)</span> Responsible for the care of a newborn infant;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(2)(c)">(c)</span> Licensed to practice medicine in Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(2)(d)">(d)</span> Board-certified by a member board of the American Board of Medical Specialties or an approved specialty board of the American Osteopathic Association in a specialty that includes the care of newborn infants.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(3)">(3)</span> “Authorized health care provider” means an individual:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(3)(a)">(a)</span> Who has received training in the screening protocol; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(3)(b)">(b)</span> For whom the CCHD screening tests are within his or her professional scope of practice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(4)">(4)</span> “Birth Defects Reporting and Information System” means the mandated reporting, monitoring, and follow-up of infants with birth defects as described in Health General Article, §18-206, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(5)">(5)</span> Birthing Facility.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(5)(a)">(a)</span> "Birthing facility" means a facility that provides care for women during labor and delivery, and their newborn infants.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(5)(b)">(b)</span> "Birthing facility" includes a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(5)(b)(i)">(i)</span> Unit of a hospital that is licensed and accredited to provide birthing services; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(5)(b)(ii)">(ii)</span> Freestanding birthing center as defined in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.05.02.01#B" title="">COMAR 10.05.02.01B</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(6)">(6)</span> “CCHD screening” means pulse oximetry testing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(7)">(7)</span> “Critical congenital heart disease (CCHD)” means a congenital heart defect that places an infant at significant risk of disability or death if not diagnosed soon after birth.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(8)">(8)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(9)">(9)</span> "Echocardiogram" means a test that uses ultrasound to provide an image of the heart.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(10)">(10)</span> "Newborn infant" means an infant in the first 28 days of life who was born:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(10)(a)">(a)</span> In Maryland; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(10)(b)">(b)</span> On federal property within Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(11)">(11)</span> "Newborn Screening Follow-Up Unit" means the unit in the Department that carries out the duties set forth in <a class="internal-link " href="/us/md/exec/comar/10.52.15.07" title=".07 Department Responsibilities.">Regulation .07 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.02#B(12)">(12)</span> “Web-based system” means the web-based database used by the Department to collect data for newborn infant screening follow-up.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.15.03" data-order="|10|52|15|.03|" data-ref-path="10|52|15|.03" class="h__section">.03 Pre-Test Information and the Right to Refuse Screening.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#A">A.</span> Before a newborn infant is screened for CCHD, a health care provider shall provide to the newborn infant's parent or guardian an explanation of CCHD screening that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#A(1)">(1)</span> Reasons for screening, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#A(1)(a)">(a)</span> The purpose and benefits of the screening; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#A(1)(b)">(b)</span> The nature, risks, and consequences of not screening for CCHD.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#A(2)">(2)</span> A parent or guardian's right to refuse having the screening performed, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#A(2)(a)">(a)</span> Explaining any risk involved with the screening; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#A(2)(b)">(b)</span> Providing a reasonable opportunity to refuse the screening.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#B">B.</span> Refusal of Screening.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#B(1)">(1)</span> All newborn infants shall be screened for CCHD unless the parent or guardian refuses the screening.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#B(2)">(2)</span> If a parent or guardian refuses screening, a provider may not perform CCHD screening on the infant.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#B(3)">(3)</span> When a parent or guardian refuses screening, the birthing facility or nurse midwife shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#B(3)(a)">(a)</span> Document parent refusal in the medical record; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#B(3)(b)">(b)</span> Enter this information into the web-based system in accordance with Regulation .05 in this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#B(4)">(4)</span> If the parent or guardian of the newborn infant does not refuse the screening, the birthing facility or nurse midwife shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#B(4)(a)">(a)</span> Perform screening on the newborn infant; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.03#B(4)(b)">(b)</span> Follow-up with results in accordance with <a class="internal-link " href="/us/md/exec/comar/10.52.15.05" title=".05 Results.">Regulation .05 of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.15.04" data-order="|10|52|15|.04|" data-ref-path="10|52|15|.04" class="h__section">.04 Screening Procedures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#A">A.</span> An authorized health care provider shall perform the screening.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#B">B.</span> Newborn Infants Receiving Routine Care.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#B(1)">(1)</span> The birthing facility or nurse midwife shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#B(1)(a)">(a)</span> Perform screening on a newborn infant between 24 hours and 48 hours of life; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#B(1)(b)">(b)</span> If unable to perform the screening, refer the infant to another authorized health care provider to perform the screening between 24 hours and 48 hours of life.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#B(2)">(2)</span> If the newborn infant is discharged from a facility after 12 hours of life but before 24 hours of life, the birthing facility shall perform screening as late as is practical before the newborn infant is discharged from the birthing facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#B(3)">(3)</span> If the newborn infant is discharged before 12 hours of life, the birthing facility shall refer the infant to another authorized health care provider to perform screening between 24 hours and 48 hours of life.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#C">C.</span> Newborn Infants in Special Care or Intensive Care. Birthing facilities shall develop protocols for screening infants in the special care or intensive care nurseries.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#D">D.</span> Circumstances Where Screening Is Not Indicated. There may be instances where screening for CCHD is not indicated, including but not limited to instances where:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#D(1)">(1)</span> The newborn infant’s clinical evaluation to date has included an echocardiogram which ruled out CCHD; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.04#D(2)">(2)</span> The newborn infant has confirmed CCHD based on prenatal or postnatal testing.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.15.05" data-order="|10|52|15|.05|" data-ref-path="10|52|15|.05" class="h__section">.05 Results.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A">A.</span> Recordation of Results.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(1)">(1)</span> All screening results shall be recorded in the newborn infant’s medical record.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)">(2)</span> All screening results shall be entered into the web-based system along with the following information:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)(a)">(a)</span> Newborn infant’s:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)(a)(i)">(i)</span> Name;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)(a)(ii)">(ii)</span> Date of birth;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)(a)(iii)">(iii)</span> Gender;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)(a)(iv)">(iv)</span> Place of birth; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)(a)(v)">(v)</span> Primary care physician after discharge; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)(b)">(b)</span> Mother’s:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)(b)(i)">(i)</span> Name; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#A(2)(b)(ii)">(ii)</span> Date of birth.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B">B.</span> Abnormal Screening Results.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B(1)">(1)</span> Abnormal screening results shall be reported by the authorized health care provider who conducted the screening to the attending physician or attending clinician immediately.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B(2)">(2)</span> A newborn infant shall be evaluated immediately by an attending physician in order to complete the recommended protocol.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B(3)">(3)</span> A newborn infant may not be discharged from care until:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B(3)(a)">(a)</span> A cause for the abnormal screening result has been determined; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B(3)(b)">(b)</span> An echocardiogram has been performed, read, and determined not to indicate CCHD.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B(4)">(4)</span> The birthing facility shall enter screening results into the web-based system as specified in <a class="internal-link " href="/us/md/exec/comar/10.52.15.05#A(2)" title="">§A(2) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B(5)">(5)</span> The birthing facility shall provide notification of abnormal results to the newborn infant’s:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B(5)(a)">(a)</span> Parent or guardian; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#B(5)(b)">(b)</span> Primary care provider.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C">C.</span> Newborn Infants Not Screened.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(1)">(1)</span> If a newborn infant is not screened secondary to discharge before 12 hours of life, the birthing facility or nurse midwife shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(1)(a)">(a)</span> Follow-up with the family to refer to an authorized health care provider for screening between 24 hours and 48 hours of life after:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(1)(a)(i)">(i)</span> Discharge from the facility; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(1)(a)(ii)">(ii)</span> A home birth; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(1)(b)">(b)</span> Enter into the web-based system the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(1)(b)(i)">(i)</span> Identifying information specified in <a class="internal-link " href="/us/md/exec/comar/10.52.15.05#A(2)" title="">§A(2) of this regulation</a>; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(1)(b)(ii)">(ii)</span> Reason for not screening which shall be “early discharge”.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(2)">(2)</span> If a newborn infant is not screened secondary to screening not being indicated, the birthing facility or nurse midwife shall enter into the web-based system:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(2)(a)">(a)</span> The identifying information specified in <a class="internal-link " href="/us/md/exec/comar/10.52.15.05#A(2)" title="">§A(2) of this regulation</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(2)(b)">(b)</span> The reason for not screening which shall be “screening not indicated”; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(2)(c)">(c)</span> A notation of the reason for the override.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(3)">(3)</span> If a newborn infant is not screened secondary to parent or guardian refusal, the birthing facility or nurse midwife shall enter into the web-based system the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(3)(a)">(a)</span> Information specified in <a class="internal-link " href="/us/md/exec/comar/10.52.15.05#A(2)" title="">§A(2) of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.05#C(3)(b)">(b)</span> Reason for not screening which shall be entered as “parent refusal”.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.15.06" data-order="|10|52|15|.06|" data-ref-path="10|52|15|.06" class="h__section">.06 Birthing Facility and Nurse Midwife Responsibilities.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A">A.</span> Birthing Facility Responsibilities. The birthing facility shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A(1)">(1)</span> Identify a clinical staff person as a contact for CCHD screening;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A(2)">(2)</span> Develop protocols to ensure that all newborn infants are offered screening;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A(3)">(3)</span> Develop protocols to ensure that all screening results are reported in accordance with <a class="internal-link " href="/us/md/exec/comar/10.52.15.05" title=".05 Results.">Regulation .05 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A(4)">(4)</span> Ensure that follow-up is performed for newborn infants not screened before hospital discharge; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A(5)">(5)</span> Develop protocols that assure the timely evaluation and referral, if necessary, of newborn infants who have abnormal screening results including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A(5)(a)">(a)</span> Evaluation by the attending physician;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A(5)(b)">(b)</span> Performance of an echocardiogram;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A(5)(c)">(c)</span> Reading of the echocardiogram; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#A(5)(d)">(d)</span> Referral of newborn infants for further evaluation when needed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.06#B">B.</span> Newborn Infants Born Outside a Birthing Facility. If the birth of a newborn infant occurs outside a birthing facility, the nurse midwife shall perform screening in accordance with <a class="internal-link " href="/us/md/exec/comar/10.52.15.05" title=".05 Results.">Regulation .05 of this chapter</a> or refer to an authorized health care provider for screening between 24 hours and 48 hours of life.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.15.07" data-order="|10|52|15|.07|" data-ref-path="10|52|15|.07" class="h__section">.07 Department Responsibilities.</h3>
                <p>The Newborn Screening Follow-Up Unit shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.07#A">A.</span> Investigate each instance of abnormal screening results to determine the cause for the abnormal result;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.07#B">B.</span> Enter newborn infants found to have CCHD into the Birth Defects Reporting and Information System;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.07#C">C.</span> Provide condition-specific information and resources to the family; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.07#D">D.</span> Perform ongoing evaluation of CCHD screening in the State.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.15.08" data-order="|10|52|15|.08|" data-ref-path="10|52|15|.08" class="h__section">.08 Records.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#A">A.</span> The screening of newborn infants pursuant to this chapter is a population-based public health surveillance program as defined under the Health Insurance Portability and Accountability Act of 1996.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#B">B.</span> On request, a birthing facility or health care provider shall make available to the Newborn Screening Follow-Up Unit:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#B(1)">(1)</span> Medical records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#B(2)">(2)</span> Records of laboratory tests; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#B(3)">(3)</span> Any other medical information the Newborn Screening Follow-Up Unit considers necessary to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#B(3)(a)">(a)</span> Determine final outcomes of abnormal screening results; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#B(3)(b)">(b)</span> Evaluate CCHD Screening activities in the State, including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#B(3)(b)(i)">(i)</span> Performance of follow-up evaluations and diagnostic tests;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#B(3)(b)(ii)">(ii)</span> Initiation of treatment when necessary; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#B(3)(b)(iii)">(iii)</span> Surveillance of the accuracy and efficacy of the screening.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#C">C.</span> Information that the Department receives under this chapter is confidential and may only be used or disclosed:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#C(1)">(1)</span> To provide services to the newborn infant and the infant's family;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#C(2)">(2)</span> To study the relationships of the various factors determining the frequency and distribution of CCHD;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#C(3)">(3)</span> For State or federally mandated statistical reports; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.15.08#C(4)">(4)</span> To ensure that the information received by the Department is accurate and reliable.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.52.16" data-order="|10|52|16|" data-ref-path="10|52|16" class="h__chapter">Chapter 16 Insect Sting Emergency Treatment Program</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: January 16, 2001 (27:25 Md. R. 2282)</p>
                  <p>——————</p>
                  <p>Chapter repealed effective December 8, 2016 (43:24 Md. R. 1350)</p>
                </section>
                <h2 id="/us/md/exec/comar/10.52.17" data-order="|10|52|17|" data-ref-path="10|52|17" class="h__chapter">Chapter 17 Maryland Asthma Control Program</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: July 31, 2006 (33:15 Md. R. 1281)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§13-1701—13-1706, Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.52.17.01" data-order="|10|52|17|.01|" data-ref-path="10|52|17|.01" class="h__section">.01 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.01#A">A.</span> The purpose of this chapter is to facilitate the implementation of the Maryland Asthma Control Program, to the extent allowed by available funding, by providing guidelines for the administration of the Asthma Coalition in its advisory capacity to the Program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.01#B">B.</span> This chapter also authorizes the Maryland Asthma Control Program to obtain asthma-related data through an asthma data surveillance system.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.17.02" data-order="|10|52|17|.02|" data-ref-path="10|52|17|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B(1)">(1)</span> "Asthma data surveillance" means the ongoing and systematic collection, analysis, and interpretation of asthma-related information for the purposes of planning, implementing, and evaluating public health interventions to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B(1)(a)">(a)</span> Prevent asthma;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B(1)(b)">(b)</span> Improve asthma health outcomes, including rates of asthma-related emergency department admissions, hospital admissions, and mortality; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B(1)(c)">(c)</span> Decrease health disparities associated with asthma.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B(2)">(2)</span> "Coalition" means the Maryland Statewide Asthma Coalition established by the Director of the Asthma Control Program under Health-General Article, §13-1704, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B(3)">(3)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B(4)">(4)</span> "Local asthma coalition" means an alliance of individuals representing personal or organizational interests whose purpose is to reduce asthma prevalence, severity, and health disparities within a particular region or jurisdiction in Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B(5)">(5)</span> "Maryland Asthma Plan" means a comprehensive strategy that provides cohesive direction, objectives, strategies, and action steps for the Coalition to use in addressing asthma in Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.02#B(6)">(6)</span> "Program" means the Maryland Asthma Control Program, which is established under Health-General Article, §13-1702, Annotated Code of Maryland.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.17.03" data-order="|10|52|17|.03|" data-ref-path="10|52|17|.03" class="h__section">.03 Establishment and Membership.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#A">A.</span> The Maryland Statewide Asthma Coalition is established.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B">B.</span> The Coalition consists of members recruited by the Director of the Maryland Asthma Control Program from each of the following organizations:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B(1)">(1)</span> The Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B(2)">(2)</span> The American Lung Association of Maryland;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B(3)">(3)</span> The Asthma and Allergy Foundation of America, Maryland-Greater Washington, D.C. Chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B(4)">(4)</span> The Johns Hopkins Medical Institutions;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B(5)">(5)</span> The University of Maryland, School of Medicine;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B(6)">(6)</span> Representatives from local health departments or local asthma coalitions;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B(7)">(7)</span> Professional health care provider organizations;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B(8)">(8)</span> Other State agencies with expertise or an interest in asthma; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.03#B(9)">(9)</span> Any other interested professional and community groups with asthma expertise.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.17.04" data-order="|10|52|17|.04|" data-ref-path="10|52|17|.04" class="h__section">.04 Quorum, Meetings, Compensation, and Staff.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.04#A">A.</span> The members of the Coalition who are present at a meeting are a quorum to do business provided that at least eight members including one co-chair attend the meeting.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.04#B">B.</span> The Coalition shall meet at least twice per year, at the times and places that a co-chair determines.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.04#C">C.</span> A member of the Coalition:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.04#C(1)">(1)</span> May not receive State-funded compensation; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.04#C(2)">(2)</span> Is not entitled to State-funded reimbursement for travel or other expenses related to serving as a Coalition member.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.04#D">D.</span> Coalition Co-Chairs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.04#D(1)">(1)</span> The Program Director or the Director's designee shall serve as a co-chair of the Coalition and designate the Program staff necessary to carry out this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.04#D(2)">(2)</span> The other co-chair shall be selected by a majority vote of a quorum of the Coalition.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.17.05" data-order="|10|52|17|.05|" data-ref-path="10|52|17|.05" class="h__section">.05 Duties.</h3>
                <p>The Coalition shall provide assistance to the Department in the development and implementation of the Program by:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.05#A">A.</span> Advising the Department on asthma-related matters, including establishing priorities within the Maryland Asthma Plan, through maintaining and sharing expertise on asthma issues;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.05#B">B.</span> Facilitating communication and networking opportunities, especially through local coalitions, groups with shared interest, and other State coalitions;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.05#C">C.</span> Increasing asthma awareness throughout the State; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.05#D">D.</span> Monitoring progress in achieving the goals established within the Maryland Asthma Plan.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.52.17.06" data-order="|10|52|17|.06|" data-ref-path="10|52|17|.06" class="h__section">.06 Asthma Data Surveillance System.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#A">A.</span> The Program shall establish a State asthma data surveillance system that has the authority to access and request the submission of data related to asthma, including the submission of a uniform data set and any confidential, patient-identifying data, or information from the following sources:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#A(1)">(1)</span> Vital Statistics Administration;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#A(2)">(2)</span> Maryland Health Care Commission;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#A(3)">(3)</span> Maryland Institute for Emergency Medical Services Systems (MIEMSS);</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#A(4)">(4)</span> Maryland Health Services Cost Review Commission;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#A(5)">(5)</span> Maryland Medical Assistance Program; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#A(6)">(6)</span> Other data sources, as necessary.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#B">B.</span> A health care provider or facility shall release confidential patient-identifying data or information to the Program in accordance with this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#C">C.</span> Any identifying data or information that the Program receives under §A or B of this regulation is confidential and may be used only for public health surveillance purposes.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#D">D.</span> A health care provider or facility may not be held liable for releasing data or other information to the Program in accordance with this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.52.17.06#E">E.</span> Except for confidential, patient-identifying medical information, the Program may publish and disseminate data or information that relates to the incidence, severity, or cost of asthma or related conditions if the Program considers the publication beneficial and in the public's interest. However, before the data or information relating to asthma is published or disseminated, the Program shall consult with any person or entity that is the source of the data the Program intends to use. The Program and the person or entity shall agree upon the manner in which the data is published or disseminated.</p>
                <hr class="section-separator" aria-hidden="true"/>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.51" aria-label="Subtitle 51 FORENSIC LABORATORIES">
                <div class="h__ui">Previous</div>
                <span>Subtitle 51 FORENSIC LABORATORIES</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.53" aria-label="Subtitle 53 BOARD OF NURSING — ELECTROLOGY PRACTICE COMMITTEE">
                <div class="h__ui">Next</div>
                <span>Subtitle 53 BOARD OF NURSING — ELECTROLOGY PRACTICE COMMITTEE</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
